T-Cell Therapy Market by Type of Therapy, Target Indication, Target Antigen, Company Size, Geographical Regions, Leading Players and Sales Forecast of Therapies, Industry Trends and Global Forecasts to 2035

The global T-cell therapy market size is estimated to grow from USD 6.5 billion in the current year to USD 20.9 billion by 2035, at a CAGR of 12% during the forecast period, till 2035.

The opportunity for the T-cell therapy market has been distributed across the following segments:

Type of Therapy

CAR-T
TCR
TIL

Target Indication

Multiple Myeloma
Large B-Cell Lymphoma
Acute Lymphoblastic Leukemia
Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Transformed Follicular Lymphoma and High grade B-cell lymphoma
Acute Lymphoblastic Leukemia / B-cell Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Mantle Cell Lymphoma
Acute Myeloid Leukemia
Generalized Myasthenia Gravis (MG)
Renal transplantation (HLA-A2)
Gastric Adenocarcinoma
Ovarian / Endometrial Cancer
Chronic Lymphocytic Leukemia
Follicular Lymphoma
Renal Cell Carcinoma
Melanoma
Basal Cell Carcinoma
Lung Cancer
Sarcoma
Head And Neck Cancer
Cervical Cancer
Neuro Gastro-Intestinal (GI) Cancer
Breast Cancer
Hepatocellular Carcinoma
Nasopharyngeal Carcinoma
Ovarian Cancer

Target Antigen

BCMA
CD19
CD20
CD19, CD22
HLA
MAGE
PRAME
NY-ESO-1 and LAGE
EBV
HBV
Others

Company Size

Small
Mid-sized
Large Research

Geographical Regions

North America
Europe
Asia-Pacific
Latin America
Middle East and North Africa
Rest of the World

T-Cell Therapy Market: Growth and Trends

T cells, a subset of white blood cells, are essential to the immunological system of the human body. The body’s reactions to external allergens and infections are tightly controlled by these cells, which efficiently identify, target, and eliminate them while recalling the first interactions to trigger a prompt and efficient immune response. Scientists have been actively researching these cells since the 19th century with an aim to leverage them to treat a wide range of medical conditions. In fact, cell therapies (specifically T cell therapies) have attracted a lot of attention lately for managing / treating hard-to-treat diseases, like cancer, autoimmune diseases, and uncommon genetic disorders, ultimately decreasing the global disease burden.

Cancer is one of the leading causes of mortality, accounting for 0.6 million deaths in 2022, in the US alone. As per the International Agency for Research on Cancer (IARC), by 2040, there are likely to be 27.5 million new cases and 16.3 million deaths related to cancer, annually. Although cancer therapeutics continue to be one of the most active areas, in terms of drug development, there are several persistent challenges in this domain. In fact, conventional cancer treatments, such as chemotherapy, surgery and radiation therapy, have demonstrated very limited efficacy in late-stage cancers.

Amidst the ongoing efforts to develop more precise and effective anti-cancer therapeutics, T-cell therapies have evolved as a promising immunotherapy that uses the body’s own immune cells to selectively eliminate tumor cells with minimal side effects. Unlike conventional therapies, immunotherapies provide several advantages, including specificity, potential reduction in off-target toxicities and improving treatment outcomes. It is worth mentioning that in 2024, the US Food and Drug Administration approved multiple T cell therapies targeting cancer (in reverse chronological order), such as Obecabtagene autoleucel / Aucatzyl (relapsed or refractory B-cell precursor acute lymphoblastic leukemia, November 2024), Afamitresgene autoleucel / TECELRA (metastatic or unresectable synovial sarcoma, August 2024) and Lifileucel / Amtagvi (unresectable or metastatic melanoma, February 2024).

Driven by the advantages offered by immunotherapies over conventional therapies, the increasing adoption of T-cell-based immunotherapies and the surge in demand for personalized cancer treatment, coupled with the expedited regulatory approvals, is expected to drive significant growth in the T cell therapeutics market. Moreover, as the global oncology landscape continues to evolve, advancements in T cell engineering and next-generation manufacturing technologies would drive innovation in this domain and position the market for steady growth in the forthcoming years.

T-Cell Therapy Market: Key Insights

The report delves into the current state of the T cell therapy market and identifies potential growth opportunities within industry. Some key findings from the report include:

With over 10 approved therapies and more than 1,200 preclinical / clinical therapy candidates, CAR-T immunotherapies represent one of the most active segments of the pharmaceutical domain.
More than 75% of the therapy candidates, which are being developed to target a range of disease indications, are autologous in nature; notably, CD19 and BCMA have emerged as the most popular target antigens.
Presently, there are over 205 TCR-based therapies that are approved / under clinical stages of development; notably, the current landscape is dominated (38%) by mid-sized players based in Europe.

Close to 35% of the TCR immunotherapies in the clinical development pipeline are being developed to target oncological disorders in adults, children and senior citizens.
Over 85 TIL-based immunotherapies have been either approved or are currently under development; of these, most of the immunotherapies are being developed by players based in North America to target melanoma.

Majority (58) of the TIL-based therapies are being used in combination with various therapeutic agents; of these, more than 45% of the immunotherapies are being developed by non-industry players.
Extensive efforts are underway to improve the CAR constructs across successive generations, involving alterations in the scFv region and using different types of gene delivery vectors.
In the last few years, over 970 clinical trials have been registered across different geographies for CAR-T therapies; extensive efforts are underway to improve successive generations of therapies.
The growing interest of stakeholders is evident from the increasing partnership activity in this domain; close to 45% of the total number of partnerships have been signed between players based in North America.
Several investors, having realized the opportunity within this upcoming segment of cancer immunotherapy, have invested more than USD 32 billion, across 370+ funding rounds in the past few years.
More than 11,900 patents related to CAR-T cell therapies have been filed / granted to protect the intellectual property generated within this field.
Apart from CAR-T, TCR and TIL-based products, close to 205 other T-cell immunotherapies are marketed / under development for the treatment of a myriad of oncological and non-oncological indications.
Close to 200 players claim to have the required capabilities to manufacture different types of cell therapies; such firms also offer a wide range of services across different stages of product development.
Given the growing prevalence of cancer, technological developments and ongoing approvals, the market for T-cell therapies is poised to witness a steady growth in the foreseen future.
With a growing focus on the development pipeline and encouraging clinical trial outcomes, the market is expected to witness an annualized growth rate of over 12%, during the next decade.

T-Cell Therapy Market: Key Segments

CAR T-cell Therapy Market Holds the Largest Share of the T-Cell Therapy Market During the Forecast Period

Based on the type of therapy, the global market is segmented into CAR-T, TCR and TIL therapies. Currently, the CAR T-cell therapy market segment captures the majority of the overall market share and is likely to dominate and drive the overall market growth. This can be attributed to the precise targeting mechanism of CAR T cell therapies that use chimeric antigen receptors to target and kill malignant cells (while minimizing damage to healthy tissues). It is worth highlighting that the TIL therapy market segment is likely to flourish during the forecast period, owing to their versatility in targeting a wide range of cancers and encouraging clinical trial results.

Therapies Targeting Melanoma Hold the Largest Share of TCR Therapies Market

Based on the target indication, the T-cell therapy market is segmented into multiple myeloma, large B-cell lymphoma, acute lymphoblastic leukemia, diffuse large b-cell lymphoma, diffuse large b-cell lymphoma, primary mediastinal large B-Cell lymphoma, transformed follicular lymphoma and high grade B-cell lymphoma, acute lymphoblastic leukemia / B-cell Non-Hodgkin lymphoma, Non-Hodgkin lymphoma, mantle cell lymphoma, acute myeloid leukemia, generalized myasthenia gravis (MG), renal transplantation (HLA-A2), gastric adenocarcinoma, ovarian / endometrial cancer, chronic lymphocytic leukemia, follicular lymphoma, renal cell carcinoma, melanoma, basal cell carcinoma, lung cancer, sarcoma, head and neck cancer, cervical cancer, neuro gastro-intestinal (GI) Cancer, breast cancer, hepatocellular carcinoma, nasopharyngeal carcinoma and ovarian cancer.

Currently, the majority share of the TCR therapies market is captured by therapies targeting melanoma (over 95%). This can be attributed to the fact that melanoma has a high rate of genetic mutations, leading to the production of many unique neoantigens which makes it a prime target for TCR therapies. Recently, the FDA has approved a TCR therapy (Kimmtrak) which is used to treat adults with metastatic uveal melanoma (a type of intraocular melanoma).

Therapies Targeting CD19 Antigen are Likely to Dominate the CAR-T Therapy market During the Forecast Period

Based on the type of target antigens, the T-cell therapy market is segmented into BCMA, CD19, CD20, CD19 and CD22, HLA, MAGE, PRAME, NY-ESO-1 and LAGE, EBV, HBV and others. Currently, therapies targeting CD19 antigen dominate the CAR-T therapies market, accounting for more than 65% of the overall market share. This dominance is primarily driven by the essential role of CD19 as it is a highly specific antigen expressed on B-cells, making it an ideal target for treating B-cell malignancies like leukemia and lymphoma.

North America Accounts for the Largest Share of the overall TCR therapy Market

Based on geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America and Middle East and North Africa, and the rest of the world. In the current scenario, North America is likely to capture the largest market share owing to the robust research and development infrastructure, a strong commercial base for cell therapies, and a high number of clinical trials being conducted in the region.

However, it is worth noting that the market for TCR therapies in Asia-Pacific is expected to grow at a relatively faster pace (CAGR of more than 45%), during the forecast period. This is driven by the increasing cases of cancer in the region, supported by the demand for curative treatments. Notably, it has been highlighted by industry experts that the cell therapy industry in China has witnessed growing interest from investment firms, enabling faster clinical research for T-cell therapies.

Key Players in the T-Cell Therapy Market

Adaptimmune Therapeutics
AbelZeta
Alaunos Therapeutics
Autolus Therapeutics
bluebird bio
Bristol Myers Squibb
CARsgen Therapeutics
Cellectis
Gilead Sciences
Immatics
Immunocore
Innovative Cellular Therapeutics
Iovance Biotherapeutics
Kuur Therapeutics
Lion TCR
Noile-Immune Biotech
Novartis
Takara Bio
Wellington Zhaotai Therapies
Zelluna immunotherapy

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Chief Executive Officer, Mid-sized Company, China
Chief Operating Officer and Executive Vice President, Small Company, France
Former Co-Founder and Chief Executive Officer, Mid-sized Company, UK
Former Chief Executive Officer, Small Company, Netherlands
Former Chief Executive Officer, Mid-sized Company, Australia
Former Vice President, Immuno-Oncology, Mid-sized Company, Belgium
Director, Business Development, Small Company, US
Former Director, Process Development, Large Company, US
Former Research Head, Large Company, US
Former Competitive Intelligence Manager, Strategy & Business Development, Small Company, US
Professor of Medicine and Director, Department of Oncology, Hospital, China
Assistant Professor of Medicine, University, US

T-Cell Therapy Market: Research Coverage

The report on T-cell therapy market features insights into various sections, including:

Market Sizing and Opportunity Analysis: An in-depth analysis of T-cell therapy market, focusing on key market segments, including [A] type of therapy, [B] target indication, [C] target antigen, [D] company size, [E] geographical regions, [F] leading players, and [G] sales forecast (of more than 55 T-cell therapies).
CAR-T cell therapies Market Landscape: A comprehensive evaluation of CAR-T cell therapies, based on several relevant parameters, such as [A] type of developer, [B] stage of development, [C] therapeutic area, [D] target indication, [E] target antigen, [F] source of T-cells, [G] route of administration, [H] dosing frequency, [I] patient segment, [J] type of therapy, [K] most active industry players, and [L] most active non-industry players.
CAR-T cell therapies Developer Landscape: The report features a list of players engaged in the development of CAR-T cell therapies offered, along with analyses based on [A] year of establishment, [B] company size, and [C] location of headquarters.
TCR-based therapies Market Landscape: A comprehensive evaluation of TCR-based therapies, based on several relevant parameters, such as [A] stage of development, [B] therapeutic area, [C] target indication, [D] target antigen, [E] source of T-cells, [F] route of administration, [G] dosing frequency, [H] target patient segment, [I] type of therapy, [J] most active industry players, and [K] most active non-industry players.
TCR-based therapies Developer Landscape: The report features a list of players engaged in the development of TCR-based therapies offered, along with analyses based on [A] year of establishment, [B] company size, and [C] location of headquarters.
TIL-based therapies Market Landscape: A comprehensive evaluation of TIL-based therapies, based on several relevant parameters, such as [A] type of developer, [B] stage of development, [C] route of administration, [D] dosing frequency, [E] patient segment, [F] type of therapy, [G] most active industry players, and [H] most active non-industry players.
TIL-based therapies Developer Landscape: The report features a list of players engaged in the development of TIL-based therapies offered, along with analyses based on [A] year of establishment, [B] company size, and [C] location of headquarters.
Key Insights Analysis: An in-depth analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies, based on various relevant parameters, such as [A] generation of CAR, [B] type of binding domain, [C] type of virus used, [D] type of gene transfer method used, and [E] type of co-stimulatory domain used.
Clinical Trial Analysis: A detailed analysis of completed, ongoing, and planned clinical studies related to CAR-Ts, TCRs, and TIL, based on several relevant parameters, such as [A] trial registration year, [B] enrolled patient population, [C] trial recruitment status, [D] trial phase, [E] target patient segment, [F] type of sponsor/collaborator, [G] most active players, and [H] regional distribution of trials.
Key Opinion Leaders (KOLs) Analysis: A comprehensive evaluation of various principal investigators (considered as key opinion leaders in this domain) involved in clinical trials related to CAR-Ts, TCRs and TILs. The section presents detailed analyses, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.
Therapy Profiles: Elaborate profiles of marketed and mid- to late-stage clinical therapies (phase I / II or above) related to CAR-Ts, TCRs and TILs, providing insights on [A] overview of the therapy, [B] mechanism of action of therapy, [C] dosage information, [D] details on the cost, and sales information (wherever available), [E] clinical development plan, and [F] key clinical trial results.
Emerging Technologies: A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers, and a relative competitiveness analysis of different gene editing platforms (used for the development of T-cell therapies), based on various parameters, such as [A] ease of system design, [B] cost of technology, [C] level of toxicity, and [D] efficiency of technology.
Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in T-Cell therapy market, based on several parameters, such as [A] year of partnership, [B] type of product, [D] type of partner, [E] most popular products, [F] most active industry players, [G] most active non-industry players and [H] geographical distribution of partnership activity.
Funding and Investment Analysis: An in-depth analysis of the fundings raised by companies that have proprietary T-cell based products/technologies, based on relevant parameters, such as [A] year of funding, [B] type of funding, [C] amount invested (USD million), [D] type of therapy, [E] type of investor, [F] most active players, [G] most active investors, and [H] geography.
Patents Analysis: An in-depth analysis of patents filed / granted till 2022 related to CAR-Ts, TCRs and TILs, based on various relevant parameters, such as [A] type of patent, [B] publication year, [C] geographical distribution, [D] Cooperative Patent Classification (CPC) symbols, [E] emerging focus areas, [F] type of applicant, [G] leading players, [H] patent benchmarking, and [I] patent valuation analysis.
Other T-Cell Immunotherapies: An overview on other T-cell-based therapies, apart from CAR-Ts, TCRs and TILs, including a detailed analysis of approved / pipeline products, which are analyzed based on various parameters, such as [A] phase of development, [B] target therapeutic area(s), [C] type of T-cells used, [D] and source of T-cells.
Case Study: A detailed assessment of manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space. It provides information about these manufacturers, focusing on details of [A] scale of operation, [B] compliance with cGMP standards, [C] location of the manufacturing facility, and [D] products being manufactured.
Cost:Price Analysis: A detailed analysis of various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a T-cell based immunotherapy that is likely to be marketed in the coming years.
Promotional Analysis: A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies, namely Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™ and TCR-based therapy (Kimmtrak®).
Company Profiles: In-depth profiles of several developers evaluating T-cell immunotherapy therapies for the treatment of various oncological and non-oncological indications, focusing on [A] company overviews, [B] financial information (if available), [C] T-cell therapy (CAR-T, TCR and TIL) specific portfolio, [D] technology portfolio (if available), [E] manufacturing capabilities (if available), [F] recent collaborations, and [G] funding and investments received by the company related to T-cell immunotherapies.

Key Questions Answered in this Report

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?
What kind of partnership models are commonly adopted by industry stakeholders?
What is the ongoing investment trend in this market?
What is the patent filing activity trend in the market?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
10% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis

2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis

2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.5. Key Considerations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.2. Currency Coverage
4.2.3. Foreign Currency Exchange Rate
4.2.4. Recession
4.2.5. Inflation
4.2.6. Interest Rates
4.2.7. Commodity Flow Analysis
4.2.8. Global Trade Dynamics 4
4.2.9. War Impact Analysis
4.2.10. COVID Impact / Related Factors
4.2.11. Other Indicators

5. EXECUTIVE SUMMARY

6. INTRODUCTION

6.1. Chapter Overview
6.2. Pillars of Cancer Therapy
6.3. Overview of Immunotherapies
6.4. Fundamentals of Cancer Immunotherapy
6.5. Classification of Cancer Immunotherapies
6.5.1. By Mechanism of Action
6.5.1.1. Active Immunotherapy
6.5.1.2. Passive Immunotherapy
6.5.2. By Type of Target
6.5.3. By Approach
6.5.3.1. Activation and Suppression Immunotherapy
6.5.4. By Product Class
6.5.4.1 Monoclonal Antibodies
6.5.4.2. Bispecific Antibodies
6.5.4.3. Cytokines
6.5.4.4. Oncolytic Virus Therapy
6.5.4.5. Therapeutic Cancer Vaccines
6.5.4.6. Cell-based Therapies
6.6. T-Cell Immunotherapies
6.6.1. Historical Evolution
6.6.2. Key Considerations for Developing T-Cell Immunotherapies
6.6.3. Strategies Employed for the Redirection of T-Cells
6.6.4. Manufacturing of Engineered T-Cells
6.6.5. T-Cell Transduction and Transfection Methods
6.6.5.1. Retroviral Vectors
6.6.5.2. Lentiviral Vectors
6.6.5.3. Non-viral Transfection Methods
6.7. Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
6.7.1. Development History
6.7.2. Anatomical Layout of CAR
6.7.2.1. Ectodomain
6.7.2.2. Transmembrane (TM) Domain
6.7.2.3. Endodomain
6.7.3. Development of CAR-T Cells
6.7.4. Universal CAR-T Cells
6.7.5. Route of Administration
6.7.6. Case Study on CD19 CAR-T Therapies
6.7.6.1. Other Important Biological Targets for CAR Development
6.7.7. Challenges Associated with Use of CAR-T Therapies
6.7.7.1. Competitive Risks
6.7.7.2. Clinical Risks
6.7.7.3. Regulatory Risks
6.7.3.4. Commercial Risks
6.8. T-Cell Receptor (TCR)-based Cell Therapy
6.8.1. Development History
6.8.2. Anatomical Layout of TCR
6.8.3. Development of TCR Therapy
6.8.4. Comparison of CAR-T and TCR-based Therapies
6.9. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapy
6.9.1. Development History
6.9.2. Development of TILs Therapy
6.10. Key Benefits and Roadblocks
6.11. Concluding Remarks

7. CAR-T THERAPIES: MARKET LANDSCAPE

7.1. Chapter Overview
7.2. CAR-T Therapies: Overall Market Landscape
7.2.1. Analysis by Stage of Development
7.2.2. Analysis by Type of Therapy
7.2.3. Analysis by Target Antigen
7.2.4. Analysis by Target Indication
7.2.5. Analysis by Therapeutic Area
7.2.6. Analysis by Stage of Development and Therapeutic Area
7.2.7. Analysis by Source of T-cells
7.2.8. Analysis by Stage of Development and Source of T-cells
7.2.9. Analysis by Route of Administration
7.2.10. Analysis by Dosing Frequency
7.2.11. Analysis by Target Patient Segment
7.2.12. Most Active Industry Players: Analysis by Number of CAR-T Therapies Developed
7.2.13. Most Active Non-Industry Players: Analysis by Number of CAR-T Therapies Developed
7.3. CAR-T Therapies: Overall Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters

8. TCR-BASED THERAPIES: MARKET LANDSCAPE

8.1. Chapter Overview
8.2. TCR-based Therapies: Approved and Clinical Pipeline
8.3. TCR-based Therapies: Preclinical Pipeline
8.4. TCR-based Therapies: Overall Market Landscape
8.4.1. Analysis by Stage of Development
8.4.2. Analysis by Therapeutic Area
8.4.3. Analysis by Stage of Development and Therapeutic Area
8.4.4. Analysis by Target Indication
8.4.5. Analysis by Target Antigen
8.4.6. Analysis by Source of T-Cells
8.4.7. Analysis by Route of Administration
8.4.8. Analysis by Dosing Frequency
8.4.9. Analysis by Target Patient Segment
8.4.10. Analysis by Type of Therapy
8.4.11. Analysis by Stage of Development and Type of Therapy
8.4.11. Most Active Industry Players: Analysis by Number of TCR-based Therapies Developed
8.4.13. Most Active Non-Industry Players: Analysis by Number of TCR-based Therapies Developed
8.5. TCR-based Therapies: Overall Developer Landscape
8.5.1. Analysis by Year of Establishment
8.5.2. Analysis by Company Size
8.5.3. Analysis by Location of Headquarters

9. TIL-BASED THERAPIES: MARKET LANDSCAPE

9.1. Chapter Overview
9.2. TIL-based Therapies: Approved and Clinical Pipeline
9.3. TIL-based Therapies: Preclinical Pipeline
9.4. TIL-based Therapies: Overall Market Landscape
9.4.1. Analysis by Type of Developer
9.4.2. Analysis by Stage of Development
9.4.3. Analysis by Route of Administration
9.4.4. Analysis by Dosing Frequency
9.4.5. Analysis by Target Patient Segment
9.4.6. Analysis by Type of Therapy
9.4.7. Analysis by Target Indication
9.4.8. Most Active Industry Players: Analysis by Number of TIL-based Therapies Developed
9.4.9. Most Active Non-Industry Players: Analysis by Number of TIL-based Therapies Developed
9.5. TIL-based Therapies: Overall Developer Landscape
9.5.1. Analysis by Year of Establishment
9.5.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters

10. KEY INSIGHTS

10.1. Chapter Overview
10.2. CAR-T Therapies: Popular Target Antigens
10.2.1. Popular Target Antigens for Hematological Malignancies
10.2.2. Popular Targets Antigens for Solid Tumors
10.3. CAR-T Therapies: CAR Construct Analysis
10.3.1. Analysis by Generation of CAR
10.3.2.Analysis by Type of scFv Antibody Used
10.3.3. Analysis by Type of Virus Used
10.3.4. Analysis by Type of Gene Transfer Method Used
10.3.5. Analysis by Type of Co-Stimulatory Domain

11. CLINICAL TRIAL ANALYSIS

11.1. Chapter Overview
11.2. Scope and Methodology
11.3. CAR-T Therapies: Clinical Trial Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis of Number of Patient Enrolled by Trial Registration Year
11.3.3. Analysis by Trial Phase
11.3.4. Analysis of Number of Patient Enrolled by Trial Phase
11.3.5. Analysis by Trial Registration Year and Trial Phase
11.3.6. Analysis by Trial Status
11.3.7. Analysis by Patient Gender
11.3.8. Analysis by Therapeutic Area
11.3.9. Analysis by Study Design
11.3.9.1. Analysis by Type of Trial Masking
11.3.9.2. Analysis by Type of Intervention Model
11.3.9.3. Analysis by Type of Trial Purpose
11.3.9.4. Analysis by Type of Design Allocation
11.3.10. Most Active Sponsor / Collaborator: Analysis by Number of Registered Trials
11.3.10.1. Analysis by Leading Industry Players
11.3.10.2. Analysis by Leading Non-Industry Players
11.3.11. Analysis by Geography
11.3.11.1. Analysis of Clinical Trials by Trial Status and Geography
11.3.11.2. Analysis of Patients Enrolled by Trail Status and Geography
11.4. TCR-based Therapies: Clinical Trial Analysis
11.4.1. Analysis by Trial Registration Year
11.4.2. Analysis by Trial Registration Year and Patient Enrolled
11.4.3. Analysis by Trial Status
11.4.4. Analysis by Trial Registration Year and Trial Status
11.4.5. Analysis by Trial Phase
11.4.6. Analysis of Patient Enrolled by Trial Phase
11.4.7. Analysis by Target Patient Segment
11.4.8. Analysis by Type of Sponsor / Collaborator
11.4.9. Analysis by Study Design
11.4.10. Most Active Industry Players: Analysis by Number of Registered Trials
11.4.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
11.4.12. Analysis by Key Focus Areas (Word Cloud Representation)
11.4.13. Analysis of Clinical Trials by Geography
11.4.14. Analysis of Patient Enrolled by Geography
11.5. TIL-based Therapies: Clinical Trial Analysis
11.5.1. Analysis by Trial Registration Year
11.5.2. Analysis by Trial Registration Year and Patient Enrolled
11.5.3. Analysis by Trial Status
11.5.4. Analysis by Trial Registration Year and Trial Status
11.5.5. Analysis by Trial Phase
11.5.6. Analysis of Patient Enrolled by Trial Phase
11.5.7. Analysis by Target Patient Segment
11.5.8. Analysis by Type of Sponsor / Collaborator
11.5.9. Analysis by Study Design
11.5.10. Most Active Industry Players: Analysis by Number of Registered Trials
11.5.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
11.5.12. Analysis by Key Focus Areas (Word Cloud Representation)
11.5.13. Analysis of Clinical Trials by Geography
11.5.14. Analysis of Patient Enrolled by Geography

12. KEY OPINION LEADERS

12.1. Chapter Overview
12.2. Assumptions and Key Parameters
12.3. Methodology
12.4. CAR-T Therapies: Key Opinion Leaders
12.4.1. Analysis by Type of Organization
12.4.2. Analysis by Affiliated Organization
12.4.3. Analysis by Qualification
12.4.4. Analysis by Geographical Location of KOLs
12.4.5. KOL Activeness versus KOL Strength
12.4.6. Most Prominent KOLs: Analysis by RA score
12.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
12.5. TCR-based Therapies: Key Opinion Leaders
12.5.1. Analysis by Type of Organization
12.5.2. Analysis by Affiliated Organization
12.5.3. Analysis by Qualification
12.5.4. Analysis by Geographical Location of KOLs
12.5.5. KOL Activeness versus KOL Strength
12.5.6. Most Prominent KOLs: Analysis by RA score
12.5.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
12.6. TIL-based Therapies: Key Opinion Leaders 12.6.1. Analysis by Type of Organization
12.6.2. Analysis by Affiliated Organization
12.6.3. Analysis by Qualification
12.6.4. Analysis by Geographical Location of KOLs
12.6.5. KOL Activeness versus KOL Strength
12.6.6. Most Prominent KOLs: Analysis by RA score
12.6.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

13. CAR-T THERAPY PROFILES

13.1. Chapter Overview
13.2. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
13.2.1. Therapy Overview
13.2.2. Clinical Trial Information
13.2.3. Clinical Trial Endpoints
13.2.4. Clinical Trial Results
13.2.5. Estimated Sales Revenues
13.3. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
13.3.1. Therapy Overview
13.3.2. Clinical Trial Information
13.3.3. Clinical Trial Endpoints
13.3.4. Clinical Trial Results
13.3.5. Estimated Sales Revenues
13.4. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
13.4.1. Therapy Overview
13.4.2. Clinical Trial Information
13.4.3. Clinical Trial Endpoints
13.4.4. Clinical Trial Results
13.4.5. Estimated Sales Revenues
13.5. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
13.5.1. Therapy Overview
13.5.2. Clinical Trial Information
13.5.3. Clinical Trial Endpoints
13.5.4. Clinical Trial Results
13.5.5. Estimated Sales Revenues
13.6. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
13.6.1. Therapy Overview
13.6.2. Clinical Trial Information
13.6.3. Clinical Trial Endpoints
13.6.4. Clinical Trial Results
13.6.5. Estimated Sales Revenues
13.7. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
13.7.1. Therapy Overview
13.7.2. Clinical Trial Information
13.7.3. Clinical Trial Endpoints
13.7.4. Clinical Trial Results
13.7.5. Estimated Sales Revenues
13.8. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
13.8.1. Therapy Overview
13.8.2. Clinical Trial Information
13.8.3. Clinical Trial Endpoints
13.8.4. Clinical Trial Results
13.8.5. Estimated Sales Revenues
13.9. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
13.9.1. Therapy Overview
13.9.2. Clinical Trial Information
13.9.3. Clinical Trial Endpoints
13.10. AUTO1 / Obecabtagene Autoleucel / obe-cel (Autolus)
13.10.1. Therapy Overview
13.10.2. Clinical Trial Information
13.10.3. Clinical Trial Endpoints
13.10.4. Clinical Trial Results
13.10.5. Estimated Sales Revenues
13.11. AUTO3 / CD19/22 CAR-T (Autolus)
13.11.1. Therapy Overview
13.11.2. Clinical Trial Information
13.11.3. Clinical Trial Endpoints
13.11.4. Clinical Trial Results
13.11.5. Estimated Sales Revenues

14. TCR-BASED THERAPY PROFILES

14.1. Chapter Overview
14.2. Kimmtrak / IMCgp100 / Tebentafusp (Immunocore)
14.2.1. Therapy Overview
14.2.2. Clinical Trial Information
14.2.3. Clinical Trial Endpoints
14.2.4. Clinical Trial Results
14.2.5. Estimated Sales Revenues
14.3. GSK3377794 / NY-ESO-1C259 T-Cells / Letetresgene Autoleucel (GlaxoSmithKline)
14.3.1. Therapy Overview
14.3.2. Clinical Trial Information
14.3.3. Clinical Trial Endpoints
14.3.4. Clinical Trial Results
14.3.5. Estimated Sales Revenues
14.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
14.4.1. Therapy Overview
14.4.2. Clinical Trial Information
14.4.3. Clinical Trial Endpoints
14.4.4. Clinical Trial Results
14.4.5. Estimated Sales Revenues
14.5. JTCR016 (Juno Therapeutics)
14.5.1. Therapy Overview
14.5.2. Clinical Trial Information
14.5.3. Clinical Trial Endpoints
14.6. TBI-1301 (Takara Bio)
14.6.1. Therapy Overview
14.6.2. Clinical Trial Information
14.6.3. Clinical Trial Endpoints
14.6.4. Clinical Trial Results
14.6.5. Estimated Sales Revenues
14.7. MDG1011 (Medigene)
14.7.1. Therapy Overview
14.7.2. Clinical Trial Information
14.7.3. Clinical Trial Endpoints
14.7.4. Clinical Trial Results

15. TIL-BASED THERAPY PROFILES

15.1. Chapter Overview
15.2. LN-144 / Lifileucel (Iovance Biotherapeutics)
15.2.1. Therapy Overview
15.2.2. Clinical Trial Information
15.2.3. Clinical Trial Endpoints
15.2.4. Clinical Trial Results
15.2.5. Estimated Sales Revenues
15.3. LN-145 (Iovance Biotherapeutics)
15.3.1. Therapy Overview
15.3.2. Clinical Trial Information
15.3.3. Clinical Trial Endpoints
15.3.4. Clinical Trial Results
15.3.5. Estimated Sales Revenues
15.4. ITIL-168 (Instil Bio)
15.4.1. Therapy Overview
15.4.2. Clinical Trial Information
15.4.3. Clinical Trial Endpoints
15.4.4. Clinical Trial Results
15.4.5. Estimated Sales Revenues
15.5. LTX-315 (Lytix Biopharma)
15.5.1. Therapy Overview
15.5.2. Clinical Trial Information
15.5.3. Clinical Trial Endpoints
15.5.4. Clinical Trial Results
15.5.5. Estimated Sales Revenues

16. EMERGING TECHNOLOGIES

16.1. Chapter Overview
16.2. Genome Editing Technologies
16.2.1. Technology Overview
16.2.2. Applications of Genome Editing Technologies
16.2.3. Emerging Technology Platforms for T-Cell Therapies
16.2.3.1. CRISPR / CAS9 System
16.2.3.1.1. Key Components
16.2.3.1.2. Mechanism of Action
16.2.3.1.3. Targeting Efficiency and Challenges
16.2.3.1.4. Next-Gen CRISPR Technology
16.2.3.1.5. Technology Providers
16.2.3.1.5.1. Intellia Therapeutics
16.2.3.1.5.2. Editas Medicine
16.2.3.1.5.3. CRISPR Therapeutics
16.2.3.1.5.4. Beam Therapeutics
16.2.3.1.5.5. Gracell Technologies
16.2.3.1.5.6. Caribou Biosciences
16.2.3.1.5.7. Nanjing Bioheng Biotech
16.2.3.1.5.8. Intima Biosciences
16.2.3.1.5.9. KSQ Therapeutics
16.2.3.1.5.10. Refuge Biotechnologies
16.2.3.2. TALENS
16.2.3.2.1. Key Components and Function
16.2.3.2.2. Mechanism of Action
16.2.3.2.3. Advantages and Challenges
16.2.3.2.4. Technology Providers
16.2.3.2.4.1. Cellectis
16.2.3.2.4.2. Editas Medicine
16.2.3.3. MegaTAL
16.2.3.3.1. Mechanism of Action
16.2.3.3.2. Technology Providers
16.2.3.3.2.1. bluebird bio
16.2.3.3.2.2. Precision Biosciences
16.2.3.4. Zinc Finger Nuclease
16.2.3.4.1. Mechanism of Action
16.2.3.4.2. Technology Providers
16.2.3.4.2.1. Sangamo Therapeutics
16.2.4. Competitive Analysis: Gene Editing Platforms
16.3. Designing T-Cell Therapies with Improved Characteristics
16.3.1. Technologies for Targeting Multiple Cancers
16.3.1.1. Antibody Coupled T-Cell Receptor
16.3.1.1.1. Cogent Biosciences
16.3.1.2. NKR-T Platform
16.3.1.2.1. Celyad
16.3.1.2.2. Glycostem
16.3.1.2.3. CatamaranBio
16.3.2. Technologies for Improved Safety
16.3.2.1. Armored CAR and EGFRt Technology
16.3.2.1.1. Juno Therapeutics
16.3.2.2. Rheoswitch Therapeutic System
16.3.2.2.1. Intrexon
16.3.2.2.2. Precigen
16.3.2.3. Inducible Caspase 9 Safety Switch
16.3.2.3.1. Bellicum Pharmaceuticals
16.3.2.3.1.1. CaspaCIDe Technology
16.3.2.3.1.2. CIDeCAR Technology
16.3.2.3.1.3. GoCAR-T Technology
16.3.2.4. On-OFF Switch, Multiple Companies
16.3.2.4.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
16.3.2.4.2. On-OFF Switch (Theravectys)
16.3.2.5. Other Technologies to Improve CAR-T Safety
16.3.3. Allogeneic Technologies
16.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals)
16.3.3.2. Allogeneic Platform (CELYAD)
16.3.3.3. Allogeneic Platform (Cellectis)
16.3.3.4. AlloCAR T (Allogene Therapeutics)
16.4. Future Perspectives

17. PARTNERSHIPS AND COLLABORATIONS

17.1. Chapter Overview
17.2. Partnership Models
17.3. T-Cell Immunotherapies Market: Partnerships and Collaborations
17.3.1. Analysis by Year of Partnership
17.3.2. Analysis by Type of Partnership
17.3.3. Analysis by Type of Product
17.3.4. Analysis by Year of Partnership and Type of Product
17.3.5. Analysis by Type of Partnership and Type of Product
17.3.6. Analysis by Type of Partner
17.3.7. Analysis by Type of Product and Type of Partner
17.3.8. Most Popular Products: Analysis by Number of Partnerships
17.3.9. Most Active Industry Players: Analysis by Number of Partnerships
17.3.10. Most Active Non-Industry Players: Analysis by Number of Partnerships
17.3.11. Analysis by Geography
17.3.11.1. Intercontinental and Intracontinental Agreements
17.3.11.2. International and Local Deals

18. FUNDING AND INVESTMENT ANALYSIS

18.1. Chapter Overview
18.2. Type of Funding
18.3. T-Cell Immunotherapy Market: Funding and Investment Analysis
18.3.1. Analysis of Instances by Year
18.3.2. Analysis of Amount Invested by Year
18.3.3. Analysis by Type of Funding
18.3.4. Analysis of Amount Invested across Different Types of Therapies
18.3.5. Analysis by Type of Investor
18.3.6. Most Active Players: Analysis by Number of Instances
18.3.7. Most Active Investors: Analysis by Amount Invested
18.3.8. Analysis of Amount Invested by Geography
18.3.9. Most Active Investors: Distribution by Number of Funding Instances

19. PATENT ANALYSIS

19.1. Chapter Overview
19.2. Scope and Methodology
19.3. Patent Analysis: Distribution by Type of Patent
19.4. CAR-T Therapies: Patent Analysis
19.4.1. Analysis by Patent Publication Year
19.4.2. Analysis by Patent Application Year
19.4.3. Analysis of Granted Patents and Patent Applications by Publication Year
19.4.4. Analysis by Patent Jurisdiction
19.4.5. Analysis by CPC Symbols
19.4.6. Analysis by Type of Applicant
19.4.7. Leading Industry Players: Analysis by Number of Patents
19.4.8. Leading Non-Industry Players: Analysis by Number of Patents
19.4.9. Leading Patent Assignees: Analysis by Number of Patents
19.4.10. CAR-T Therapies: Patent Benchmarking
19.4.11. Analysis of Patent Characteristics
19.4.12. CAR-T Therapies: Patent Valuation
19.4.13. Leading Patents by Number of Citations
19.5. TCR-based Therapies: Patent Analysis
19.5.1. Analysis by Patent Publication Year
19.5.2. Analysis by Patent Application Year
19.5.3. Analysis by Geography
19.5.4. Analysis by Type of Player
19.5.5. Analysis by CPC Symbols
19.5.6. Analysis by Key Focus Areas
19.5.7. Leading Players: Analysis by Number of Patents
19.5.8. TCR-based Therapies: Patent Benchmarking
19.5.9 Analysis by Patent Characteristics
19.5.10. TCR-based Therapies: Patent Valuation
19.6. TIL-based Therapies: Patent Analysis
19.6.1. Analysis by Patent Publication Year
19.6.2. Analysis by Patent Application Year
19.6.3. Analysis by Geography
19.6.4. Analysis by Type of Player
19.6.5. Analysis by CPC Symbols
19.6.6. Analysis by Key Focus Areas
19.6.7. Leading Players: Analysis by Number of Patents
19.6.8. TIL-based Therapies: Patent Benchmarking
19.6.9. Analysis by Patent Characteristics
19.6.10. TIL-based Therapies: Patent Valuation

20. OTHER T-CELL IMMUNOTHERAPIES

20.1. Chapter Overview
20.2. Other T-Cell Immunotherapies
20.2.1. Fucosylated T-Cell Therapies
20.2.2. Gamma Delta T-Cell Therapies
20.2.3. PD-1 Knockout Engineered T-Cell Therapies
20.2.4. TAC T-Cell Therapies
20.2.5. T-Cell Vaccines
20.2.6. Treg Cell Therapies
20.2.7. Virus-Driven T-Cell Therapies

20.3. Other T-Cell Immunotherapies: Market Landscape
20.3.1. Analysis by Type of T-Cell
20.3.2. Analysis by Source of T-Cell
20.3.3. Analysis by Stage of Development
20.3.4. Analysis by Therapeutic Area

20.4. Key Considerations for Developing T-Cell Immunotherapies
20.5. Concluding Remarks

21. CASE STUDY: CELL THERAPY MANUFACTURING

21.1. Chapter Overview
21.2. Overview of Cell Therapy Manufacturing
21.3. Cell Therapy Manufacturing Models
21.3.1. Centralized Manufacturing Model
21.3.2. Decentralized Manufacturing Model

21.4. Scalability of Cell Therapy Manufacturing Processes
21.4.1. Scale-Up
21.4.2. Scale-Out

21.5. Types of Cell Therapy Manufacturers
21.6. Key Challenges Related to Manufacturing of Cell Therapies

21.7. Important Factors for Cell Therapy Manufacturing
21.7.1. Characterization
21.7.2. Cost of Goods

21.8. Automation of Cell Therapy Manufacturing Process
21.9. Cell Therapy Manufacturing Supply Chain
21.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers
21.11. Regulatory Landscape
21.12. Future Perspectives

22. COST PRICE ANALYSIS

22.1. Chapter Overview
22.2. Factors Contributing to the High Price of Cell / Gene Therapies
22.3. Pricing Models for T-Cell Immunotherapies
22.3.1. Based on Associated Costs
22.3.2. Based on Availability of Competing Products
22.3.3. Based on Patient Segment
22.3.4. Based on Opinions of Industry Experts

22.4. Reimbursement related Considerations for T-Cell Immunotherapies
22.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T therapies

23. GLOBAL T-CELL THERAPIES MARKET

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Global T-Cell Therapies Market, Historical Trends (since 2018) and Future Estimates (till 2035)

23.4. Scenario Analysis
23.4.1. Conservative Scenario
23.4.2. Optimistic Scenario

23.5. Key Market Segmentations

24. T-CELL THERAPIES MARKET, BY TYPE OF THERAPY

24.1. Chapter Overview
24.2. Key Assumptions and Methodology

24.3. T-Cell Therapies Market: Distribution by Type of Therapy
24.3.1. T-Cell Therapies Market for CAR-T: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
24.3.2. T-Cell Therapies Market for TCR: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
24.3.3. T-Cell Therapies Market for TIL: Forecasted Estimates (till 2035)

24.4. Data Triangulation and Validation

25. T-CELL THERAPIES MARKET, BY TARGET INDICATION

25.1. Chapter Overview
25.2. Key Assumptions and Methodology

25.3. CAR-T Therapies Market: Distribution by Target Indication
25.3.1. CAR-T Therapies Market for Multiple Myeloma: Forecasted Estimates (till 2035)
25.3.2. CAR-T Therapies Market for Large B-Cell Lymphoma: Forecasted Estimates (till 2035)
25.3.3. CAR-T Therapies Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (till 2035)
25.3.4. CAR-T Therapies Market for Diffuse Large B-Cell Lymphoma: Forecasted Estimates (till 2035)
25.3.5. CAR-T Therapies Market for Diffuse Large B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Transformed Follicular Lymphoma and High grade B-cell lymphoma: Forecasted Estimates (till 2035)
25.3.6. CAR-T Therapies Market for Acute Lymphoblastic Leukemia/ B-cell Non-Hodgkin Lymphoma: Forecasted Estimates (till 2035)
25.3.7. CAR-T Therapies Market for Non-Hodgkin Lymphoma: Forecasted Estimates (till 2035)
25.3.8. CAR-T Therapies Market for Mantle Cell Lymphoma: Forecasted Estimates (till 2035)
25.3.9. CAR-T Therapies Market for Acute Myeloid Leukemia: Forecasted Estimates (till 2035)
25.3.10. CAR-T Therapies Market for Generalized Myasthenia Gravis: Forecasted Estimates (till 2035)
25.3.11. CAR-T Therapies Market for Renal transplantation (HLA-A2): Forecasted Estimates (till 2035)
25.3.12. CAR-T Therapies Market for Gastric Adenocarcinoma: Forecasted Estimates (till 2035)
25.3.13. CAR-T Therapies Market for Ovarian / Endometrial cancer: Forecasted Estimates (till 2035)
25.3.14. CAR-T Therapies Market for Chronic Lymphocytic Leukemia: Forecasted Estimates (till 2035)
25.3.15. CAR-T Therapies Market for Follicular Lymphoma: Forecasted Estimates (till 2035)
25.3.16. CAR-T Therapies Market for Renal Cell Carcinoma: Forecasted Estimates (till 2035)

25.4. TCR Therapies Market: Distribution by Target Indication
25.4.1. TCR Therapies Market for Melanoma: Forecasted Estimates (till 2035)
25.4.2. TCR Therapies Market for Sarcoma: Forecasted Estimates (till 2035)
25.4.3. TCR Therapies Market for Head and Neck Cancer: Forecasted Estimates (till 2035)
25.4.4. TCR Therapies Market for Hepatocellular Carcinoma: Forecasted Estimates (till 2035)
25.4.5. TCR Therapies Market for Nasopharyngeal Carcinoma: Forecasted Estimates (till 2035)
25.4.6. TCR Therapies Market for Ovarian Cancer: Forecasted Estimates (till 2035)
25.4.7. TCR Therapies Market for Acute Myeloid Leukemia: Forecasted Estimates (till 2035)

25.5. TIL Therapies Market: Distribution by Target Indication
25.5.1. TIL Therapies Market for Melanoma: Forecasted Estimates (till 2035)
25.5.2. TIL Therapies Market for Basal Cell Carcinoma: Forecasted Estimates (till 2035)
25.5.3. TIL Therapies Market for Lung Cancer: Forecasted Estimates (till 2035)
25.5.4. TIL Therapies Market for Sarcoma: Forecasted Estimates (till 2035)
25.5.5. TIL Therapies Market for Head and Neck Cancer: Forecasted Estimates (till 2035)
25.5.6. TIL Therapies Market for Cervical Cancer: Forecasted Estimates (till 2035)
25.5.7. TIL Therapies Market for Neuro Gastro-Intestinal (GI) Cancer: Forecasted Estimates (till 2035)
25.5.8. TIL Therapies Market for Breast Cancer: Forecasted Estimates (till 2035)

25.6. Data Triangulation and Validation

26. T-CELL THERAPIES MARKET, BY TARGET ANTIGEN

26.1. Chapter Overview
26.2. Key Assumptions and Methodology

26.3. CAR-T Therapies Market: Distribution by Type Target Antigen
26.3.1. CAR-T Therapies Market for BCMA: Forecasted Estimates (till 2035)
26.3.2. CAR-T Therapies Market for CD19: Forecasted Estimates (till 2035)
26.3.3. CAR-T Therapies Market for CD20: Forecasted Estimates (till 2035)
26.3.4. CAR-T Therapies Market for CD19 / CD22: Forecasted Estimates (till 2035)
26.3.5. CAR-T Therapies Market for Other Target Antigens: Forecasted Estimates (till 2035)

26.4. TCR Therapies Market: Distribution by Type Target Antigen
26.4.1. TCR Therapies Market for HLA: Forecasted Estimates (till 2035)
26.4.2. TCR Therapies Market for MAGE: Forecasted Estimates (till 2035)
26.4.3. TCR Therapies Market for PRAME: Forecasted Estimates (till 2035)
26.4.4. TCR Therapies Market for NY-ESO-1 and LAGE: Forecasted Estimates (till 2035)
26.4.5. TCR Therapies Market for EBV: Forecasted Estimates (till 2035)
26.4.6. TCR Therapies Market for HBV: Forecasted Estimates (till 2035)

26.5. Data Triangulation and Validation

27. T-CELL THERAPIES MARKET, BY COMPANY SIZE

27.1. Chapter Overview
27.2. Key Assumptions and Methodology

27.3. TCR Therapies Market: Distribution by Company Size
27.3.1. TCR Therapies Market for Mid-sized Companies: Forecasted Estimates (till 2035)
27.3.2. TCR Therapies Market for Large Companies: Forecasted Estimates (till 2035)

27.4. TIL Therapies Market: Distribution by Company Size
27.4.1. TIL Therapies Market for Small Companies: Forecasted Estimates (till 2035)
27.4.2. TIL Therapies Market for Large Companies: Forecasted Estimates (till 2035)

27.5. Data Triangulation and Validation

28. T-CELL THERAPIES MARKET, BY GEOGRAPHICAL REGIONS

28.1. Chapter Overview
28.2. Key Assumptions and Methodology

28.3. CAR-T Therapies Market: Distribution by Geographical Regions
28.3.1. CAR-T Therapies Market in North America: Forecasted Estimates (till 2035)
28.3.2. CAR-T Therapies Market in Europe: Forecasted Estimates (till 2035)
28.3.3. CAR-T Therapies Market in Asia-Pacific: Forecasted Estimates (till 2035)
28.3.4. CAR-T Therapies Market in Latin America: Forecasted Estimates (till 2035)
28.3.5. CAR-T Therapies Market in Middle East and North Africa: Forecasted Estimates (till 2035)
28.3.6. CAR-T Therapies Market in Rest of the World: Forecasted Estimates (till 2035)

28.4. CAR-T Therapies Market, by Geographical Regions: Market Dynamics Assessment
28.4.1 Penetration Growth (P-G) Matrix
28.4.2 Market Movement Analysis

28.5. TCR Therapies Market: Distribution by Geographical Regions
28.5.1. TCR Therapies Market in North America: Forecasted Estimates (till 2035)
28.5.2. TCR Therapies Market in Europe: Forecasted Estimates (till 2035)
28.5.3. TCR Therapies Market in Asia-Pacific: Forecasted Estimates (till 2035)
28.5.4. TCR Therapies Market in Rest of the World: Forecasted Estimates (till 2035)

28.6. TCR Therapies Market, by Geographical Regions: Market Dynamics Assessment
28.6.1 Penetration Growth (P-G) Matrix
28.6.2 Market Movement Analysis

28.7. TIL Therapies Market: Distribution by Geographical Regions
28.7.1. TIL Therapies Market in North America: Forecasted Estimates (till 2035)
28.7.2. TIL Therapies Market in Europe: Forecasted Estimates (till 2035)
28.7.3. TIL Therapies Market in Rest of the World: Forecasted Estimates (till 2035)

28.8. TIL Therapies Market, by Geographical Regions: Market Dynamics Assessment
28.8.1 Penetration Growth (P-G) Matrix
28.8.2 Market Movement Analysis

28.9. Data Triangulation and Validation

29. T-CELL THERAPY MARKET, BY LEADING PLAYERS

29.1. Chapter Overview
29.2. Key Assumptions and Methodology

29.3. CAR-T Therapies: Sales Forecast of Leading Players
29.3.1. Gilead Sciences Sales Forecast
29.3.2. Bristol Myers Squibb Sales Forecast
29.3.3. Novartis Sales Forecast
29.3.4. Janssen Sales Forecast
29.3.5. JW Therapeutics Sales Forecast

29.4. TCR Therapies: Sales Forecast of Leading Players
29.4.1. Immunocore Sales Forecast
29.4.2. Adaptimmune Therapeutics Sales Forecast
29.4.3. TCRCure Biopharma Sales Forecast
29.4.4. Lion TCR Sales Forecast
29.4.5. Miltenyi Biomedicine Sales Forecast

29.5. TIL Therapies: Sales Forecast of Leading Players
29.5.1. Iovance Biotherapeutics Sales Forecast
29.5.2. Lytix Biopharma Sales Forecast
29.5.3. Bristol-Myers Squibb Sales Forecast
29.5.4. Intima Bioscience Sales Forecast

29.6. Data Triangulation and Validation

30. T-CELL THERAPIES MARKET, SALES FORECAST OF THERAPIES

30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Commercialized CAR-T Therapies: Sales Forecast
30.3.1. Kymriah (Tisagenlecleucel-T) Sales Forecast
30.3.2. Yescarta (axicabtagene ciloleucel) Sales Forecast
30.3.3. Tecartus (Brexucabtagene Autoleucel) Sales Forecast
30.3.4. Abecma (Idecabtagene Vicleucel / bb211211) Sales Forecast
30.3.5. CARVYKTI (LCAR-B38M CAR-T / JNJ-6821845218 / Ciltacabtagene Autoleucel) Sales Forecast
30.3.6. BREYANZI (Lisocabtagene maraleucel, JCAR017) Sales Forecast
30.3.7. Carteyva (Relmacabtagene autoleucel / JWCAR0219) Sales Forecast
30.3.8. NexCART Sales Forecast
30.3.9. Fucaso (Equecabtagene Autoleucel) Sales Forecast
30.3.10. Inaticabtagene Autoleucel CNCT19 / HY001Sales Forecast
30.3.11. Zevorcabtagene autoleucel (CT053) Sales Forecast

30.4. Clinical CAR-T Therapies: Sales Forecast
30.4.1. CAR-BCMA T cells Sales Forecast
30.4.2. CAR-T-CD19 Cells Sales Forecast
30.4.3. Descartes-08 Sales Forecast
30.4.4. Zamtocabtagene Autoleucel (MB-CART21019.1) Sales Forecast
30.4.5. CAR-T ddBCMA Sales Forecast
30.4.6. CRG-02121 cells Sales Forecast
30.4.7. CT041 Sales Forecast
30.4.8. ALLO-501A / ALLO-501 Sales Forecast
30.4.9. ALLO-605 Sales Forecast
30.4.10. Descartes-25 Sales Forecast
30.4.11. AUTO1 Sales Forecast
30.4.12. AUTO3 (CD19/2121 CAR-T) Sales Forecast
30.4.13. AUTO4 (CD19/2121 CAR-T) Sales Forecast
30.4.14. CD19-CAR-T Sales Forecast
30.4.15. Humanized CD19-CAR-T Sales Forecast
30.4.16. IM19 CAR-T Sales Forecast
30.4.17. CCT301 CAR-T Sales Forecast
30.4.18. CARCIK-CD19 Sales Forecast
30.4.19. CD123 CAR-T cells Sales Forecast
30.4.20. BCMA CAR-T Sales Forecast
30.4.21. CD19/CD22-CAR-T Sales Forecast
30.4.22. GC012F (Dual CAR-BCMA-19) Sales Forecast
30.4.23. CD19/CD210-CART Sales Forecast
30.4.24. CD7 CAR-T Sales Forecast
30.4.25. Anti-FLT3 CAR-T / TAA05 Sales Forecast
30.4.26. Anti-ALPP CAR-T Cells Sales Forecast
30.4.27. WU CART 007 Sales Forecast
30.4.28. CTX110 Sales Forecast
30.4.29. TX2100-TR101 Sales Forecast
30.4.30. ALETA-001 Sales Forecast
30.4.31. PBCAR0191 Sales Forecast

30.5. Commercialized TCR Therapies: Sales Forecast
30.5.1. Kimmtrak (IMCgp100 / Tebentafusp) Sales Forecast
30.5.2. TECELRA® (Afamitresgene Autoleucel) Sales Forecast

30.6. Clinical TCR Therapies: Sales Forecast
30.6.1. Brenetafusp (IMC-F106C) Sales Forecast
30.6.2. lete-cel Sales Forecast
30.6.3. ADP-A2M4CD8 Sales Forecast
30.6.4. EBV-specific TCR-T cell with anti-PD1 auto-secreted element Sales Forecast
30.6.5. Unnamed TCR therapy Sales Forecast
30.6.6. MB-dNPM1 Sales Forecast

30.7. Commercialized TIL Therapies: Sales Forecast
30.7.1. AMTAGVI Sales Forecast

30.8. Clinical TIL Therapies: Sales Forecast
30.8.1. LN-145 Sales Forecast
30.8.2. IOV-4001 Sales Forecast
30.8.3. LTX-315 and TILs Sales Forecast
30.8.4. TILs Sales Forecast
30.8.5. TIL (Cyclophosphamide) Sales Forecast

30.9. Data Triangulation and Validation

31. PROMOTIONAL ANALYSIS

31.1. Chapter Overview
31.2. Channels Used for Promotional Campaigns
31.3. Summary of Product Website Analysis
31.4. Summary of Patient Support Services and Informative Downloads
31.5. Kymriah: Promotional Analysis
31.5.1. Drug Overview
31.5.2. Product Website Analysis
31.5.2.1. Message for Healthcare Professionals
31.5.2.2. Message for Patients
31.5.2.3. Informative Downloads

31.5.3. Patient Support Services

31.6. Yescarta: Promotional Analysis
31.6.1. Drug Overview
31.6.2. Product Website Analysis
31.6.2.1. Message for Healthcare Professionals
31.6.2.2. Message for Patients
31.6.2.3. Informative Downloads

31.6.3. Patient Support Services

31.7. Tecartus: Promotional Analysis
31.7.1. Drug Overview
31.7.2. Product Website Analysis
31.7.2.1. Message for Healthcare Professionals
31.7.2.2. Message for Patients
31.7.2.3. Informative Downloads

31.7.3. Patient Support Services

31.8. Breyanzi: Promotional Analysis
31.8.1. Drug Overview
31.8.2. Product Website Analysis
31.8.2.1. Message for Healthcare Professionals
31.8.2.2. Message for Patients
31.8.2.3. Informative Downloads

31.8.3. Patient Support Services

31.9. Abecma: Promotional Analysis
31.9.1. Drug Overview
31.9.2. Product Website Analysis
31.9.2.1. Message for Healthcare Professionals
31.9.2.2. Message for Patients
31.9.2.3. Informative Downloads

31.9.3. Patient Support Services

31.10. Carvykti: Promotional Analysis
31.10.1. Drug Overview
31.10.2. Product Website Analysis
31.10.2.1. Message for Healthcare Professionals
31.10.2.2. Message for Patients
31.10.2.3. Informative Downloads

31.10.3. Patient Support Services

31.11. Kimmtrak: Promotional Analysis
31.11.1. Drug Overview
31.11.2. Product Website Analysis
31.11.2.1. Message for Healthcare Professionals
31.11.2.2. Message for Patients
31.11.2.3. Informative Downloads

31.11.3. Patient Support Services

32. COMPANY PROFILES

32.1. Chapter Overview
32.2. Adaptimmune Therapeutics
32.3. AbelZeta
32.4. Alaunos Therapeutics
32.5. Autolus Therapeutics
32.6. Bluebird Bio
32.7. Bristol Myers Squibb
32.8. Carsgen Therapeutics
32.9. Cellectis
32.10. Gilead Sciences
32.11. Immatics
32.12. Immunocore
32.13. Innovative Cellular Therapeutics
32.14. Iovance Biotherapeutics
32.15. Kuur Therapeutics
32.16. Lion TCR
32.17. Noile-Immune Biotech
32.18. Novartis
32.19. Takara Bio
32.20. Wellington Zhaotai Therapies
32.21. Zelluna immunotherapy

33. CONCLUDING REMARKS

34. EXECUTIVE INSIGHTS

34.1. Chapter Overview
34.2. Mid-sized Company, China
34.2.1. Interview Transcript: Chief Executive Officer

34.3. Small Company, France
34.3.1. Interview Transcript: Chief Operating Officer and Executive Vice President

34.4. Mid-sized, UK
34.4.1. Interview Transcript: Former Co-Founder and Chief Executive Officer

34.5. Small Company, Netherlands
34.5.1. Interview Transcript: Former Chief Executive Officer

34.6. Mid-sized Company, Australia
34.6.1. Interview Transcript: Former Chief Executive Officer

34.7. Mid-sized Company, Belgium
34.7.1. Interview Transcript: Former Vice President, Immuno-Oncology

34.8. Small Company, US
34.8.1. Interview Transcript: Director, Business Development

34.9. Large Company, US
34.9.1. Interview Transcript: Former Director, Process Development

34.10. Large Company, US
34.10.1. Interview Transcript: Former Research Head

34.11. Small Company, US
34.11.1. Interview Transcript: Former Competitive Intelligence Manager, Strategy and Business Development

34.12. Hospital, China
34.12.1. Interview Transcript: Professor of Medicine and Director, Department of Oncology

34.13. University, US
34.13.1. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

35. APPENDIX 1: TABULATED DATA36. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Overall Market Landscape
Figure 5.2 Executive Summary: Recent Trends Analysis
Figure 5.3 Executive Summary: Market Sizing and Opportunity Analysis
Figure 6.1 Pillars of Cancer Therapy
Figure 6.2 Differences between Active and Passive Immunotherapies
Figure 6.3 Differences between Specific and Non-Specific Immunotherapies
Figure 6.4 Strategies Employed for the Redirection of T-Cells
Figure 6.5 T-Cell Manufacturing: General Procedure
Figure 6.6 Development History of CAR-T cells
Figure 6.7 Structure of Chimeric Antigen Receptor
Figure 6.8 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 6.9 CAR-T Therapies: Development Process
Figure 6.10 Challenges Associated with CAR-T Therapies
Figure 6.11 TCR-based Therapies: Development Process
Figure 6.12 TIL-based Therapies: Development Process
Figure 6.13 T-Cell Immunotherapies: Benefits and Roadblocks
Figure 7.1 CAR-T Therapies: Distribution by Stage of Development
Figure 7.2 CAR-T Therapies: Distribution by Type of Therapy
Figure 7.3 CAR-T Therapies: Distribution by Target Antigen
Figure 7.4 CAR-T Therapies: Distribution by Target Indication
Figure 7.5 CAR-T Therapies: Distribution by Therapeutic Area
Figure 7.6 CAR-T Therapies: Distribution by Stage of Development and Therapeutic Area
Figure 7.7 CAR-T Therapies: Distribution by Source of T-cells
Figure 7.8 CAR-T Therapies: Distribution by Stage of Development and Source of T-cells
Figure 7.9 CAR-T Therapies: Distribution by Route of Administration
Figure 7.10 CAR-T Therapies: Distribution by Dosing Frequency
Figure 7.11 CAR-T Therapies: Distribution by Target Patient Segment
Figure 7.12 Most Active Industry Players: Distribution by Number of CAR-T Therapies Developed
Figure 7.13 Most Active Non-Industry Players: Distribution by Number of CAR-T Therapies Developed
Figure 7.14 CAR-T Therapies Developers: Distribution by Year of Establishment
Figure 7.15 CAR-T Therapies Developers: Distribution by Company Size
Figure 7.16 CAR-T Therapies Developers: Distribution by Location of Headquarters (Region)
Figure 7.17 CAR-T Therapies Developers: Distribution by Location of Headquarters (Country)
Figure 8.1 TCR-based Therapies: Distribution by Stage of Development
Figure 8.2 TCR-based Therapies: Distribution by Therapeutic Area
Figure 8.3 TCR-based Therapies: Distribution by Stage of Development and Therapeutic Area
Figure 8.4 TCR-based Therapies: Distribution by Target Indication
Figure 8.5 TCR-based Therapies: Distribution by Target Antigen
Figure 8.6 TCR-based Therapies: Distribution by Source of T-Cells
Figure 8.7 TCR-based Therapies: Distribution by Route of Administration
Figure 8.8 TCR-based Therapies: Distribution by Dosing Frequency
Figure 8.9 TCR-based Therapies: Distribution by Target Patient Segment
Figure 8.10 TCR-based Therapies: Distribution by Type of Therapy
Figure 8.11 TCR-based Therapies: Distribution by Stage of Development and Type of Therapy
Figure 8.12 Most Active Industry Players: Distribution by Number of TCR-based Therapies Developed
Figure 8.13 Most Active Non-Industry Players: Distribution by Number of TCR-based Therapies Developed
Figure 8.14 TCR-based Therapy Developers: Distribution by Year of Establishment
Figure 8.15 TCR-based Therapy Developers: Distribution by Company Size
Figure 8.16 TCR-based Therapy Developers: Distribution by Location of Headquarters
Figure 9.1 TIL-based Therapies: Distribution by Type of Developer
Figure 9.2 TIL-based Therapies: Distribution by Stage of Development
Figure 9.3 TIL-based Therapies: Distribution by Route of Administration
Figure 9.4 TIL-based Therapies: Distribution by Dosing Frequency
Figure 9.5 TIL-based Therapies: Distribution by Target Patient Segment
Figure 9.6 TIL-based Therapies: Distribution by Type of Therapy
Figure 9.7 TIL-based Therapies: Distribution by Target Indications
Figure 9.8 Most Active Industry Players: Distribution by Number of TIL-based Therapies Developed
Figure 9.9 Most Active Non-Industry Players: Distribution by Number of TIL-based Therapies Developed
Figure 9.10 TIL-based Therapy Developers: Distribution by Year of Establishment
Figure 9.11 TIL-based Therapy Developers: Distribution by Company Size
Figure 9.12 TIL-based Therapy Developers: Distribution by Location of Headquarters
Figure 10.1 CAR-T Therapies: Popular Targets in Hematological Malignancies
Figure 10.2 CAR-T Therapies: Popular Targets in Solid Tumors
Figure 10.3 CAR-Construction: Distribution by Generation of CAR-T Therapies
Figure 10.4 CAR-Construction: Distribution by Type of scFv Antibody Used
Figure 10.5 CAR-Construction: Distribution by Type of Virus Used
Figure 10.6 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Figure 10.7 CAR-Construction: Distribution by Type of Co-Stimulatory Domain
Figure 11.1 Clinical Trial Analysis: Scope and Methodology
Figure 11.2 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2017
Figure 11.3 Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year, Since 2017
Figure 11.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 11.5 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Figure 11.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Since 2017
Figure 11.7 Clinical Trial Analysis: Distribution by Trial Status
Figure 11.8 Clinical Trial Analysis: Distribution by Patient Gender
Figure 11.9 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 11.10 Clinical Trial Analysis: Distribution by Type of Trial Masking
Figure 11.11 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 11.12 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 11.13 Clinical Trial Analysis: Distribution by Design Allocation
Figure 11.14 Leading Industry Players: Distribution by Number of Registered Trials
Figure 11.15 Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 11.16 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Figure 11.17 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Figure 11.18 TCR-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since 2017
Figure 11.19 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Patient Enrolled, Since 2017
Figure 11.20 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Figure 11.21 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Since 2017
Figure 11.22 TCR-based Therapies Clinical Trial Analysis: Distribution of Number of Trials by Trial Phase
Figure 11.23 TCR-based Therapies Clinical Trial Analysis: Distribution of Patient Enrolled by Trial Phase
Figure 11.24 TCR-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 11.25 TCR-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 11.26 TCR-based Therapies Clinical Trial Analysis: Distribution by Study Design
Figure 11.27 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 11.28 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 11.29 TCR-based Therapies Clinical Trial Analysis: Emerging Focus Areas
Figure 11.30 TCR-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 11.31 TCR-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 11.32 TCR-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 11.33 TCR-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 11.34 TIL-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since 2017
Figure 11.35 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Patient Enrolled, Since 2017
Figure 11.36 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Figure 11.37 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Since 2017
Figure 11.38 TIL-based Therapies Clinical Trial Analysis: Distribution of Number of Trials by Trial Phase
Figure 11.39 TIL-based Therapies Clinical Trial Analysis: Distribution of Patient Enrolled by Trial Phase
Figure 11.40 TIL-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 11.41 TIL-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 11.42 TIL-based Therapies Clinical Trial Analysis: Distribution by Study Design
Figure 11.43 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 11.44 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 11.45 TIL-based Therapies Clinical Trial Analysis: Emerging Focus Areas
Figure 11.46 TIL-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 11.47 TIL-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 11.48 TIL-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 11.49 TIL-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 12.1 CAR-T Therapies KOL Analysis: Distribution by Type of Organization
Figure 12.2 CAR-T Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 12.3 CAR-T Therapies KOL Analysis: Distribution by Qualification
Figure 12.4 CAR-T Therapies KOL Analysis: Distribution by Geography
Figure 12.5 CAR-T Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 12.6 CAR-T Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 12.7 CAR-T Therapies Most Prominent KOLs: Distribution by RA Score
Figure 12.8 CAR-T Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 12.9 CAR-T Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 12.10 TCR-based Therapies KOL Analysis: Distribution by Type of Organization
Figure 12.11 TCR-based Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 12.12 TCR-based Therapies KOL Analysis: Distribution by Qualification
Figure 12.13 TCR-based Therapies KOL Analysis: Distribution by Geography
Figure 12.14 TCR-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 12.15 TCR-based Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 12.16 TCR-based Therapies Most Prominent KOLs: Distribution by RA Score
Figure 12.17 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 12.18 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 12.19 TIL-based Therapies KOL Analysis: Distribution by Type of Organization
Figure 12.20 TIL-based Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 12.21 TIL-based Therapies KOL Analysis: Distribution by Qualification
Figure 12.22 TIL-based Therapies KOL Analysis: Distribution by Geography
Figure 12.23 TIL-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 12.24 TIL-based Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 12.25 TIL-based Therapies Most Prominent KOLs: Distribution by RA Score
Figure 12.26 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 12.27 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 13.1 Kymriah: Estimated Sales Revenues
Figure 13.2 Yescarta: Estimated Sales Revenues
Figure 13.3 Tecartus: Estimated Sales Revenues
Figure 13.4 Breyanzi: Estimated Sales Revenues
Figure 13.5 Abecma: Estimated Sales Revenues
Figure 13.6 Carvykti: Estimated Sales Revenues
Figure 13.7 Carteyva: Estimated Sales Revenues
Figure 13.8 AUTO1: Estimated Sales Revenues
Figure 13.9 AUTO3: Estimated Sales Revenues
Figure 14.1 Kimmtrak: Estimated Sales Revenues
Figure 14.2 GSK3377794: Estimated Sales Revenues
Figure 14.3 ADP-A2M4: Estimated Sales Revenues
Figure 14.4 TBI-1301: Estimated Sales Revenues
Figure 15.1 LN-144: Estimated Sales Revenues
Figure 15.2 LN-145: Estimated Sales Revenues
Figure 15.3 ITIL-168: Estimated Sales Revenues
Figure 15.4 LTX-315: Estimated Sales Revenues
Figure 16.1 Genome Editing Technologies: Applications
Figure 16.2 Genome Editing: Emerging Technology Platforms Used in T-Cell Therapies
Figure 16.3 TALEN: Mechanism of Action
Figure 16.4 MegaTAL: Mechanism of Action
Figure 16.5 Zinc Finger Nuclease: Mechanism of Action
Figure 16.6 Competitiveness Analysis: Gene Editing Platforms
Figure 16.7 T-Cell Therapy: Key Technologies to Enhance Features / Characteristics
Figure 16.8 Cellectis: Properties of Enhanced T-Cell Platform
Figure 16.9 Cellectis: Allogeneic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 17.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Since 2015
Figure 17.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 17.3 Partnerships and Collaborations: Distribution by Type of Partnership, Since 2015
Figure 17.4 Partnerships and Collaborations: Distribution by Type of Product
Figure 17.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
Figure 17.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 17.7 Partnerships and Collaborations: Distribution by Type of Partner
Figure 17.8 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Since 2015
Figure 17.9 Partnerships and Collaborations: Distribution by Type of Product and Type of Partner
Figure 17.10 Most Popular Products: Distribution by Number of Partnerships
Figure 17.11 Most Active Industry Players: Distribution by Number of Partnerships
Figure 17.12 Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 17.13 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Figure 17.14 Partnerships and Collaborations: Distribution of International and Local Deals
Figure 18.1 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Since 2018
Figure 18.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Since 2018 (USD Million)
Figure 18.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 18.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 18.5 Funding and Investments: Distribution of Amount Invested by Type of Therapy, Since 2018
Figure 18.6 Funding and Investments: Distribution by Types of Investors
Figure 18.7 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Figure 18.8 Most Active Players: Distribution by Number of Instances
Figure 18.9 Most Active Players: Distribution by Amount Invested
Figure 18.10 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Figure 18.11 Most Active Investors: Distribution by Number of Amount Invested
Figure 19.1 Patent Analysis: Distribution by Type of Patent
Figure 19.2 CAR-T Therapies Patent Analysis: Cumulative Year-wise Trend by Patent Publication Year, Since 2017
Figure 19.3 CAR-T Therapies Patent Analysis: Cumulative Year-wise Trend by Patent Application Year, Since 2017
Figure 19.4 CAR-T Therapies Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, Since 2017
Figure 19.5 CAR-T Therapies Patent Analysis: Distribution by Patent Jurisdiction
Figure 19.6 CAR-T Therapies Patent Analysis: Distribution by CPC Symbols
Figure 19.7 CAR-T Therapies Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 19.8 Leading Industry Players: Distribution by Number of Patents
Figure 19.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 19.10 Leading Individual Assignees: Distribution by Number of Patents
Figure 19.11 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 19.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 19.13 CAR-T Therapies Patent Analysis: Distribution by Patent Age
Figure 19.14 CAR-T Therapies: Patent Valuation
Figure 19.15 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 19.16 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 19.17 TCR-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 19.18 TCR-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 19.19 TCR-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted Patents
Figure 19.20 TCR-based Therapies Patent Analysis: Distribution by Geography
Figure 19.21 TCR-based Therapies Patent Analysis: Distribution by Type of Player
Figure 19.22 TCR-based Therapies Patent Analysis: Distribution by CPC Symbol
Figure 19.23 TCR-based Therapies Patent Analysis: Key Focus Area
Figure 19.24 Leading Industry Players: Distribution by Number of Patents
Figure 19.25 Leading Non-Industry Players: Distribution by Number of Patents
Figure 19.26 Leading Patent Assignees: Distribution by Number of Patents
Figure 19.27 Patent Analysis (Top 10 CPC Symbols): Benchmarking by Leading Players
Figure 19.28 TCR-based Therapies Patent Analysis: Distribution by Patent Age
Figure 19.29 TCR-based Therapies: Patent Valuation Analysis
Figure 19.30 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 19.31 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 19.32 TIL-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 19.33 TIL-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 19.34 TIL-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted Patents
Figure 19.35 TIL-based Therapies Patent Analysis: Distribution by Geography
Figure 19.36 TIL-based Therapies Patent Analysis: Distribution by Type of Player
Figure 19.37 TIL-based Therapies Patent Analysis: Distribution by CPC Symbols
Figure 19.38 TIL-based Therapies Patent Analysis: Key Focus Area
Figure 19.39 Leading Industry Players: Distribution by Number of Patents
Figure 19.40 Leading Non-Industry Players: Distribution by Number of Patents
Figure 19.41 Leading Patent Assignees: Distribution by Number of Patents
Figure 19.42 Patent Analysis (Top 10 CPC Symbols): Benchmarking by Leading
Figure 19.43 TIL-based Therapies Patent Analysis: Distribution by Patent Age
Figure 19.44 TIL-based Therapies: Patent Valuation Analysis
Figure 20.1 Mechanism of Action of Gamma Delta T-Cells
Figure 20.2 Mechanism of Action of PD-1 Knockout Engineered T-Cell Therapies
Figure 20.3 Functions of Treg Cells
Figure 20.4 Other T-Cell Immunotherapies: Distribution by Type of T-Cell
Figure 20.5 Other T-Cell Immunotherapies: Distribution by Stage of Development
Figure 20.6 Other T-Cell Immunotherapies: Distribution by Therapeutic Area
Figure 20.7 Other T-Cell Immunotherapies: Distribution by Source of T-Cells
Figure 21.1 Steps for Manufacturing Cell Therapies
Figure 21.2 Centralized Manufacturing: Process Model
Figure 21.3 Decentralized Manufacturing: Process Model
Figure 21.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 21.5 Cell Therapy: Challenges and Drivers
Figure 21.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 21.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 21.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 22.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 23.1 Global T-Cell Therapies Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 23.2 Global T-Cell Therapies Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Billion)
Figure 23.3 Global T-Cell Therapies Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Billion)
Figure 24.1 T-Cell Therapies Market: Distribution by Type of Therapy (USD Billion)
Figure 24.2 T-Cell Therapies Market for CAR-T: Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 24.3 T-Cell Therapies Market for TCR: Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 24.4 T-Cell Therapies Market for TIL: Forecasted Estimates (till 2035) (USD Billion)
Figure 25.1 CAR-T Therapies Market: Distribution by Target Indication
Figure 25.2 CAR-T Therapies Market for Multiple Myeloma: Forecasted Estimates (till 2035) (USD Million)
Figure 25.3 CAR-T Therapies Market for Large B-Cell Lymphoma: Forecasted Estimates (till 2035) (USD Million)
Figure 25.4 CAR-T Therapies Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (till 2035) (USD Million)
Figure 25.5 CAR-T Therapies Market for Diffuse Large B-Cell Lymphoma: Forecasted Estimates (till 2035) (USD Million)
Figure 25.6 CAR-T Therapies Market for Diffuse Large B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Transformed Follicular Lymphoma and High grade B-cell lymphoma: Forecasted Estimates (till 2035) (USD Million)
Figure 25.7 CAR-T Therapies Market for Acute Lymphoblastic Leukemia / B-cell Non-Hodgkin Lymphoma: Forecasted Estimates (till 2035) (USD Million)
Figure 25.8 CAR-T Therapies Market for Non-Hodgkin Lymphoma: Forecasted Estimates (till 2035) (USD Million)
Figure 25.9 CAR-T Therapies Market for Mantle Cell Lymphoma: Forecasted Estimates (till 2035) (USD Million)
Figure 25.10 CAR-T Therapies Market for Acute Myeloid Leukemia: Forecasted Estimates (till 2035) (USD Million)
Figure 25.11 CAR-T Therapies Market for Generalized Myasthenia Gravis: Forecasted Estimates (till 2035) (USD Million)
Figure 25.12 CAR-T Therapies Market for Renal Transplantation (HLA-A2): Forecasted Estimates (till 2035) (USD Million)
Figure 25.13 CAR-T Therapies Market for Gastric Adenocarcinoma: Forecasted Estimates (till 2035) (USD Million)
Figure 25.14 CAR-T Therapies Market for Ovarian / Endometrial Cancer: Forecasted Estimates (till 2035) (USD Million)
Figure 25.15 CAR-T Therapies Market for Chronic Lymphocytic Leukemia: Forecasted Estimates (till 2035) (USD Million)
Figure 25.16 CAR-T Therapies Market for Follicular Lymphoma: Forecasted Estimates (till 2035) (USD Million)
Figure 25.17 CAR-T Therapies Market for Renal Cell Carcinoma: Forecasted Estimates (till 2035) (USD Million)
Figure 25.18 TCR Therapies Market: Distribution by Target Indication
Figure 25.19 TCR Therapies Market for Melanoma: Forecasted Estimates (till 2035) (USD Million)
Figure 25.20 TCR Therapies Market for Sarcoma: Forecasted Estimates (till 2035) (USD Million)
Figure 25.21 TCR Therapies Market for Head and Neck Cancer: Forecasted Estimates (till 2035) (USD Million)
Figure 25.22 TCR Therapies Market for Hepatocellular Carcinoma: Forecasted Estimates (till 2035) (USD Million)
Figure 25.23 TCR Therapies Market for Nasopharyngeal Carcinoma: Forecasted Estimates (till 2035) (USD Million)
Figure 25.24 TCR Therapies Market for Ovarian Cancer: Forecasted Estimates (till 2035) (USD Million)
Figure 25.25 TCR Therapies Market for Acute Myeloid Leukemia: Forecasted Estimates (till 2035) (USD Million)
Figure 25.26 TIL Therapies Market: Distribution by Target Indication
Figure 25.28 TIL Therapies Market for Melanoma: Forecasted Estimates (till 2035) (USD Million)
Figure 25.29 TIL Therapies Market for Basal Cell Carcinoma: Forecasted Estimates (till 2035) (USD Million)
Figure 25.30 TIL Therapies Market for Lung Cancer: Forecasted Estimates (till 2035) (USD Million)
Figure 25.31 TIL Therapies Market for Sarcoma: Forecasted Estimates (till 2035) (USD Million)
Figure 25.32 TIL Therapies Market for Head and Neck Cancer: Forecasted Estimates (till 2035) (USD Million)
Figure 25.33 TIL Therapies Market for Cervical Cancer: Forecasted Estimates (till 2035) (USD Million)
Figure 25.34 TIL Therapies Market for Neuro Gastro-Intestinal (GI) Cancer: Forecasted Estimates (till 20355) (USD Million)
Figure 25.35 TIL Therapies Market for Breast Cancer: Forecasted Estimates (till 2035) (USD Million)
Figure 26.1 CAR-T Therapies Market: Distribution by Target Antigen
Figure 26.2 CAR-T Therapies Market for BCMA: Forecasted Estimates (till 2035) (USD Million)
Figure 26.3 CAR-T Therapies Market for CD19: Forecasted Estimates (till 2035) (USD Million)
Figure 26.4 CAR-T Therapies Market for CD20: Forecasted Estimates (till 2035) (USD Million)
Figure 26.5 CAR-T Therapies Market for CD19 / CD22: Forecasted Estimates (till 2035) (USD Million)
Figure 26.6 CAR-T Therapies Market for Other Antigens: Forecasted Estimates (till 2035) (USD Million)
Figure 26.7 TCR Therapies Market: Distribution by Target Antigen
Figure 26.8 TCR Therapies Market for HLA: Forecasted Estimates (till 2035) (USD Million)
Figure 26.9 TCR Therapies Market for MAGE: Forecasted Estimates (till 2035) (USD Million)
Figure 26.10 TCR Therapies Market for PRAME: Forecasted Estimates (till 2035) (USD Million)
Figure 26.11 TCR Therapies Market for NY-ESO-1 and LAGE: Forecasted Estimates (till 2035) (USD Million)
Figure 26.12 TCR Therapies Market for EBV: Forecasted Estimates (till 2035) (USD Million)
Figure 26.13 TCR Therapies Market for HBV: Forecasted Estimates (till 2035) (USD Million)
Figure 27.1 TCR Therapies Market: Distribution by Company Size
Figure 27.2 TCR Therapies Market for Mid-Sized Companies: Forecasted Estimates (till 2035) (USD Million)
Figure 27.3 TCR Therapies Market for Large Companies: Forecasted Estimates (till 2035) (USD Million)
Figure 27.4 TIL Therapies Market: Distribution by Company Size
Figure 27.5 TIL Therapies Market for Small Companies: Forecasted Estimates (till 2035) (USD Million)
Figure 27.6 TIL Therapies Market for Large Companies: Forecasted Estimates (till 2035) (USD Million)
Figure 28.1 CAR-T Therapies Market: Distribution by Geographical Regions
Figure 28.2 CAR-T Therapies Market in North America: Forecasted Estimates (till 2035) (USD Million)
Figure 28.3 CAR-T Therapies Market in Europe: Forecasted Estimates (till 2035) (USD Million)
Figure 28.4 CAR-T Therapies Market in Asia-Pacific: Forecasted Estimates (till 2035) (USD Million)
Figure 28.5 CAR-T Therapies Market in Latin America: Forecasted Estimates (till 2035) (USD Million)
Figure 28.6 CAR-T Therapies Market in Middle East and North Africa: Forecasted Estimates (till 2035) (USD Million)
Figure 28.7 CAR-T therapies Market in Rest of the World: Forecasted Estimates (till 2035) (USD Million)
Figure 28.8 Penetration Growth (P-G) Matrix: Geographical Regions
Figure 28.9 Market Movement Analysis: Geographical Regions
Figure 28.10 TCR Therapies Market: Distribution by Geographical Regions
Figure 28.11 TCR Therapies Market in North America: Forecasted Estimates (till 2035) (USD Million)
Figure 28.12 TCR Therapies Market in Europe: Forecasted Estimates (till 2035) (USD Million)
Figure 28.13 TCR Therapies Market in Asia-Pacific: Forecasted Estimates (till 2035) (USD Million)
Figure 28.14 TCR therapies Market in Rest of the World: Forecasted Estimates (till 2035) (USD Million)
Figure 28.15 Penetration Growth (P-G) Matrix: Geographical Regions
Figure 28.16 Market Movement Analysis: Geographical Regions
Figure 28.17 TIL Therapies Market: Distribution by Geographical Regions
Figure 28.18 TIL Therapies Market in North America: Forecasted Estimates (till 2035) (USD Million)
Figure 28.19 TIL Therapies Market in Europe: Forecasted Estimates (till 2035) (USD Million)
Figure 28.20 TIL therapies Market in Rest of the World: Forecasted Estimates (till 2035) (USD Million)
Figure 28.21 Penetration Growth (P-G) Matrix: Geographical Regions
Figure 28.22 Market Movement Analysis: Geographical Regions
Figure 29.1 CAR-T Therapies Market: Distribution by Sales Forecast of Leading Players
Figure 29.2 CAR-T Therapies Market: Gilead Sciences Sales Forecast, till 2035 (USD Million)
Figure 29.3 CAR-T Therapies Market: Bristol Myers Squibb Sales Forecast, till 2035 (USD Million)
Figure 29.4 CAR-T Therapies Market: Novartis Sales Forecast, till 2035 (USD Million)
Figure 29.5 CAR-T Therapies Market: Janssen Sales Forecast, till 2035 (USD Million)
Figure 29.6 CAR-T Therapies Market: JW Therapeutics Sales Forecast, till 2035 (USD Million)
Figure 29.7 TCR Therapies Market: Distribution by Sales Forecast of Leading Players
Figure 29.8 TCR Cell Therapies Market: Immunocore Sales Forecast, till 2035 (USD Million)
Figure 29.9 TCR Therapies Market: Adaptimmune Therapeutics Sales Forecast, till 2035 (USD Million)
Figure 29.10 TCR Therapies Market: TCRCure Biopharma Sales Forecast, till 2035 (USD Million)
Figure 29.11 TCR Therapies Market: Lion TCR Sales Forecast, till 2035 (USD Million)
Figure 29.12 TCR Therapies Market: Miltenyi Biomedicine Sales Forecast, till 2035 (USD Million)
Figure 29.13 TIL Therapies Market: Distribution by Sales Forecast of Leading Players
Figure 29.14 TIL Therapies Market: Iovance Biotherapeutics Sales Forecast, till 2035 (USD Million)
Figure 29.15 TIL Therapies Market: Lytix Biopharma Sales Forecast, till 2035 (USD Million)
Figure 29.16 TIL Therapies Market: Bristol-Myers Squibb Sales Forecast, till 2035 (USD Million)
Figure 29.17 TIL Therapies Market: Intima Bioscience Sales Forecast, till 2035 (USD Million)
Figure 30.1 CAR-T Therapies Market: Kymriah (Tisagenlecleucel-T) Sales Forecast, till 2035 (USD Million)
Figure 30.2 CAR-T Therapies Market: Yescarta (axicabtagene ciloleucel) Sales Forecast, till 2035 (USD Million)
Figure 30.3 CAR-T Therapies Market: Tecartus (Brexucabtagene Autoleucel) Sales Forecast, till 2035 (USD Million)
Figure 30.4 CAR-T Therapies Market: Abecma (Idecabtagene Vicleucel / bb2121) Sales Forecast, till 2035 (USD Million)
Figure 30.5 CAR-T Therapies Market: CARVYKTI (LCAR-B38M CAR-T / JNJ-68284528 / Ciltacabtagene Autoleucel) Sales Forecast, till 2035 (USD Million)
Figure 30.6 CAR-T Therapies Market: BREYANZI (Lisocabtagene maraleucel, JCAR017) Sales Forecast, till 2035 (USD Million)
Figure 30.7 CAR-T Therapies Market: Carteyva (Relmacabtagene autoleucel / JWCAR029) Sales Forecast, till 2035 (USD Million)
Figure 30.8 CAR-T Therapies Market: NexCART Sales Forecast, till 2035 (USD Million)
Figure 30.9 CAR-T Therapies Market: Fucaso (Equecabtagene Autoleucel) Sales Forecast, till 2035 (USD Million)
Figure 30.10 CAR-T Therapies Market: Inaticabtagene Autoleucel CNCT19 / HY001 Sales Forecast, till 2035 (USD Million)
Figure 30.11 CAR-T Therapies Market: Zevorcabtagene autoleucel (CT053) Sales Forecast, till 2035 (USD Million)
Figure 30.12 CAR-T Therapies Market: CAR-BCMA T cells Sales Forecast, till 2035 (USD Million)
Figure 30.13 CAR-T Therapies Market: CAR-T-CD19 Cells Sales Forecast, till 2035 (USD Million)
Figure 30.14 CAR-T Therapies Market: Descartes-08 Sales Forecast, 2029-2035 (USD Million)
Figure 30.15 CAR-T Therapies Market: Zamtocabtagene Autoleucel (MB-CART2019.1) Sales Forecast, till 2035 (USD Million)
Figure 30.16 CAR-T Therapies Market: CAR-T ddBCMA Sales Forecast, till 2035 (USD Million)
Figure 30.17 CAR-T Therapies Market: CRG-022 cells Sales Forecast, till 2035 (USD Million)
Figure 30.18 CAR-T Therapies Market: CT041 Sales Forecast, till 2035 (USD Million)
Figure 30.19 CAR-T Therapies Market: ALLO-501A / ALLO-501 Sales Forecast, till 2035 (USD Million)
Figure 30.20 CAR-T Therapies Market: ALLO-605 Sales Forecast, till 2035 (USD Million)
Figure 30.21 CAR-T Therapies Market: Descartes-25 Sales Forecast, till 2035 (USD Million)
Figure 30.22 CAR-T Therapies Market: AUTO1 Sales Forecast, till 2035 (USD Million)
Figure 30.23 CAR-T Therapies Market: AUTO3 (CD19/22 CAR-T) Sales Forecast, till 2035 (USD Million)
Figure 30.24 CAR-T Therapies Market: AUTO4 (CD19/22 CAR-T) Sales Forecast, till 2035 (USD Million)
Figure 30.25 CAR-T Therapies Market: CD19-CAR-T Sales Forecast, till 2035 (USD Million)
Figure 30.26 CAR-T Therapies Market: Humanized CD19-CAR-T Sales Forecast, till 2035 (USD Million)
Figure 30.27 CAR-T Therapies Market: IM19 CAR-T Sales Forecast, till 2035 (USD Million)
Figure 30.28 CAR-T Therapies Market: CCT301 CAR-T Sales Forecast, till 2035 (USD Million)
Figure 30.29 CAR-T Therapies Market: CARCIK-CD19 Sales Forecast, till 2035 (USD Million)
Figure 30.30 CAR-T Therapies Market: CD123 CAR-T cells Sales Forecast, till 2035 (USD Million)
Figure 30.31 CAR-T Therapies Market: BCMA CAR-T Sales Forecast, till 2035 (USD Million)
Figure 30.32 CAR-T Therapies Market: CD19/CD22-CAR-T Sales Forecast, till 2035 (USD Million)
Figure 30.33 CAR-T Therapies Market: GC012F (Dual CAR-BCMA-19) Sales Forecast, till 2035 (USD Million)
Figure 30.34 CAR-T Therapies Market: CD19/CD20-CART Sales Forecast, till 2035 (USD Million)
Figure 30.35 CAR-T Therapies Market: CD7 CAR-T Sales Forecast, till 2035 (USD Million)
Figure 30.36 CAR-T Therapies Market: Anti-FLT3 CAR-T / TAA05 Sales Forecast, till 2035 (USD Million)
Figure 30.37 CAR-T Therapies Market: Anti-ALPP CAR-T Cells Sales Forecast, till 2035 (USD Million)
Figure 30.38 CAR-T Therapies Market: WU CART 007 Sales Forecast, till 2035 (USD Million)
Figure 30.39 CAR-T Therapies Market: CTX110 Sales Forecast, till 2035 (USD Million)
Figure 30.40 CAR-T Therapies Market: TX200-TR101 Sales Forecast, till 2035 (USD Million)
Figure 30.41 CAR-T Therapies Market: ALETA-001 Sales Forecast, till 2035 (USD Million)
Figure 30.42 CAR-T Therapies Market: PBCAR0191 Sales Forecast, till 2035 (USD Million)
Figure 30.43 TIL Therapies Market: Kimmtrak (IMCgp100 / Tebentafusp) Sales Forecast, till 2035 (USD Million)
Figure 30.44 TIL Therapies Market: TECELRA® (Afamitresgene Autoleucel) Sales Forecast, till 2035 (USD Million)
Figure 30.45 TCR Therapies Market: Brenetafusp (IMC-F106C) Sales Forecast, till 2035 (USD Million)
Figure 30.46 TCR Therapies Market: lete-cel Sales Forecast, till 2035 (USD Million)
Figure 30.47 TCR Therapies Market: ADP-A2M4CD8 Sales Forecast, till 2035 (USD Million)
Figure 30.48 TCR Therapies Market: EBV-specific TCR-T cell with anti-PD1 auto-secreted element Sales Forecast, till 2035 (USD Million)
Figure 30.49 TCR Therapies Market: Unnamed TCR Therapy, till 2035 (USD Million)
Figure 30.50 TCR Therapies Market: MB-dNPM1, till 2035 (USD Million)
Figure 30.51 TIL Therapies Market: AMTAGVI Sales Forecast, till 2035 (USD Million)
Figure 30.52 TIL Therapies Market: LN-145 Sales Forecast, till 2035 (USD Million)
Figure 30.53 TIL Therapies Market: IOV-4001Sales Forecast, till 2035 (USD Million)
Figure 30.54 TIL Therapies Market: LTX-315 and TILs Sales Forecast, till 2035 (USD Million)
Figure 30.55 TIL Therapies Market: TILs Sales Forecast, till 2035 (USD Million)
Figure 30.56 TIL Therapies Market: TIL (Cyclophosphamide) Sales Forecast, till 2035 (USD Million)
Figure 31.1 Channels Used for Promotional Campaigns
Figure 31.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 31.3 Product Website Analysis: Kymriah, Messages for Healthcare Professionals
Figure 31.4 Product Website Analysis: Kymriah, Messages for Patients
Figure 31.5 Product Website Analysis: Kymriah, Patient Support Program
Figure 31.6 Product Website Analysis: Yescarta, Messages for Healthcare Professionals
Figure 31.7 Product Website Analysis: Yescarta, Messages for Patients
Figure 31.8 Product Website Analysis: Yescarta, Kite Konnect
Figure 31.9 Product Website Analysis: Yescarta, Platform for Referral Patient Treatment and Connecting with Treatment Center
Figure 31.10 Product Website Analysis: Tecartus, Messages for Healthcare Professionals
Figure 31.11 Product Website Analysis: Tecartus, Messages for Patients
Figure 31.12 Product Website Analysis: Tecartus, Kite Konnect
Figure 31.13 Product Website Analysis: Breyanzi, Messages for Healthcare Professional
Figure 31.14 Product Website Analysis: Breyanzi, Messages for Patients
Figure 31.15 Product Website Analysis: Breyanzi, Cell Therapy 360
Figure 31.16 Product Website Analysis: Abecma, Messages for Healthcare Professional
Figure 31.17 Product Website Analysis: Abecma, Messages for Patients
Figure 31.18 Product Website Analysis: Abecma, Cell Therapy 360
Figure 31.19 Product Website Analysis: Carvykti, Messages for Healthcare Professional
Figure 31.20 Product Website Analysis: Carvykti, Messages for Patients
Figure 31.21 Product Website Analysis: Carvykti, MyCARVYKTI
Figure 31.22 Product Website Analysis: Kimmtrak, Messages for Healthcare Professional
Figure 31.23 Product Website Analysis: Kimmtrak, Messages for Patients
Figure 31.24 Product Website Analysis: Kimmtrak, Kimmtrak Connect
Figure 33.1 Concluding Remarks: CAR-T Therapies Market Landscape
Figure 33.2 Concluding Remarks: TCR Therapies Market Landscape
Figure 33.3 Concluding Remarks: TIL Therapies Market Landscape
Figure 33.4 Concluding Remarks: Clinical Trial Analysis
Figure 33.5 Concluding Remarks: Partnerships and Collaborations
Figure 33.6 Concluding Remarks: Funding and Investments Analysis
Figure 33.7 Concluding Remarks: Patent Analysis
Figure 33.8 Concluding Remarks: Market Forecast and Opportunity Analysis

LIST OF TABLES

Table 6.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 6.2 FDA Approved Antibody based Cancer Therapeutics
Table 6.3 Retroviral Vectors: Salient Features
Table 6.4 Lentiviral Vectors: Salient Features
Table 6.5 Key Characteristics of CAR-T Cells
Table 6.6 Comparison of First and Second-Generation CAR-Ts
Table 6.7 CD19 CAR-T Cells: Preclinical Results
Table 6.8 Other Targets under Clinical / Preclinical Studies for CAR-T Therapies
Table 6.9 CAR-T and TCR-based Therapies: Key Differences
Table 7.1 CAR-T Therapies: Approved and Clinical Pipeline
Table 7.2 CAR-T Therapies: Information on Route of Administration, Source of T-cell, Dosing Frequency, and Target Patient Segment
Table 7.3 CAR-T Therapy: Preclinical Pipeline
Table 7.4 List of CAR-T Therapy Developers
Table 8.1 TCR-based Therapies: Approved and Clinical Pipeline
Table 8.2 TCR-based Therapies: Information on Sponsor, Stage of Development, Route of Administration, Dosing Frequency, Target Patient Segment and Type of Therapy
Table 8.3 TCR-based Therapies: Preclinical Pipeline
Table 8.4 List of TCR-based Therapies: List of Developers
Table 9.1 TIL-based Therapies: Approved and Clinical Pipeline
Table 9.2 TIL-based Therapies: Information on Sponsor, Stage of Development, Route of Administration, Dosing Frequency, Target Patient Segment and Type of Therapy
Table 9.3 TIL-based Therapies: Preclinical Pipeline
Table 9.4 TIL-based Therapies: List of Developers
Table 10.1 CAR-T Therapies: Information on CAR-Constructs of Clinical Candidates
Table 12.1 CAR-T Therapies: List of Principal Investigators
Table 12.2 TCR-based Therapies: List Principal Investigators
Table 12.3 TIL-based Therapies: List of Principal Investigators
Table 13.1 CAR-T Therapies: List of Therapies Profiled
Table 13.2 Therapy Profile: Kymriah® (Novartis)
Table 13.3 Kymriah®: Clinical Trial Information
Table 13.4 Kymriah®: Clinical Trial Endpoints
Table 13.5 Kymriah®: Clinical Trial Results
Table 13.6 Therapy Profile: Yescarta® (Gilead Sciences)
Table 13.7 Yescarta®: Clinical Trial Information
Table 13.8 Yescarta®: Clinical Trial Endpoints
Table 13.9 Yescarta®: Clinical Trial Results
Table 13.10 Therapy Profile: Tecartus™ (Gilead Sciences)
Table 13.11 Tecartus™: Clinical Trial Information
Table 13.12 Tecartus™: Clinical Trial Endpoints
Table 13.13 Tecartus™: Clinical Trial Results
Table 13.14 Therapy Profile: Breyanzi® (Bristol Myers Squibb)
Table 13.15 Breyanzi®: Clinical Trial Information
Table 13.16 Breyanzi®: Clinical Trial Endpoints
Table 13.17 Breyanzi®: Clinical Trial Results
Table 13.18 Therapy Profile: Abecma (Bristol Myers Squibb)
Table 13.19 Abecma: Clinical Trial Information
Table 13.20 Abecma: Clinical Trial Endpoints
Table 13.21 Abecma: Clinical Trial Results
Table 13.22 Therapy Profile: Carvykti (Janssen)
Table 13.23 Carvykti: Clinical Trial Information
Table 13.24 Carvykti: Clinical Trial Endpoints
Table 13.25 Carvykti: Clinical Trial Results
Table 13.26 Therapy Profile: Carteyva (JW Therapeutics)
Table 13.27 Carteyva: Clinical Trial Information
Table 13.28 Carteyva: Clinical Trial Endpoints
Table 13.29 Carteyva: Clinical Trial Results
Table 13.30 Therapy Profile: TBI-1501 (Takara Bio)
Table 13.31 TBI-1501: Clinical Trial Information
Table 13.32 TBI-1501: Clinical Trial Endpoints
Table 13.33 Therapy Profile: AUTO1 (Autolus)
Table 13.34 AUTO1: Clinical Trial Information
Table 13.35 AUTO1: Clinical Trial Endpoints
Table 13.36 AUTO1: Clinical Trial Results
Table 13.37 Therapy Profile: AUTO3 (Autolus)
Table 13.38 AUTO3: Clinical Trial Information
Table 13.39 AUTO3: Clinical Trial Endpoints
Table 13.40 AUTO3: Clinical Trial Results
Table 14.1 TCR Therapies: List of Therapies Profiled
Table 14.2 Therapy Profile: Kimmtrak (Immunocore)
Table 14.3 Kimmtrak: Clinical Trial Information
Table 14.4 Kimmtrak: Clinical Trial Endpoints
Table 14.5 Kimmtrak: Clinical Trial Results
Table 14.6 Therapy Profile: GSK3377794 (GlaxoSmithKline)
Table 14.7 GSK3377794: Clinical Trial Information
Table 14.8 GSK3377794: Clinical Trial Endpoints
Table 14.9 GSK3377794: Clinical Trial Results
Table 14.10 Therapy Profile: ADP-A2M4 (Adaptimmune Therapeutics)
Table 14.11 ADP-A2M4: Clinical Trial Information
Table 14.12 ADP-A2M4: Clinical Trial Endpoints
Table 14.13 ADP-A2M4: Clinical Trial Results
Table 14.14 Therapy Profile: JTCR016 (Juno Therapeutics (Bristol Myers Squibb))
Table 14.15 JTCR016: Clinical Trial Information
Table 14.16 JTCR016: Clinical Trial Endpoints
Table 14.17 Therapy Profile: TBI-1301 (Takara Bio)
Table 14.18 TBI-1301: Clinical Trial Information
Table 14.19 TBI-1301: Clinical Trial Endpoints
Table 14.20 TBI-1301: Clinical Trial Results
Table 14.21 Therapy Profile: MDG1011 (Medigene)
Table 14.22 MDG1011: Clinical Trial Information
Table 14.23 MDG1011: Clinical Trial Endpoints
Table 14.24 MDG1011: Clinical Trial Results
Table 15.1 TIL Therapies: List of Therapies Profiled
Table 15.2 Therapy Profile: LN-144 (Iovance Biotherapeutics)
Table 15.3 LN-144: Clinical Trial Information
Table 15.4 LN-144: Clinical Trial Endpoints
Table 15.5 LN-144: Clinical Trial Results
Table 15.6 Therapy Profile: LN-145 (Iovance Biotherapeutics)
Table 15.7 LN-145: Clinical Trial Information
Table 15.8 LN-145: Clinical Trial Endpoints
Table 15.9 LN-145: Clinical Trial Results
Table 15.10 Therapy Profile: ITIL-168 (Instil Bio)
Table 15.11 ITIL-168: Clinical Trial Information
Table 15.12 ITIL-168: Clinical Trial Endpoints
Table 15.13 ITIL-168: Clinical Trial Results
Table 15.14 Therapy Profile: LTX-315 (Lytix Biopharma)
Table 15.15 LTX-315: Clinical Trial Information
Table 15.16 LTX-315: Clinical Trial Endpoints
Table 15.17 LTX-315: Clinical Trial Results
Table 16.1 Bellicum Pharmaceuticals: Key Switch Technologies
Table 16.2 Technologies For CAR-T Safety Enhancement
Table 17.1 T-Cell Immunotherapies Market: List of Partnerships and Collaborations, 2005-2022
Table 18.1 T-Cell Immunotherapies: Funding and Investments, 2000-2022
Table 18.2 T-Cell Immunotherapies: Summary of Investments
Table 19.1 CAR-T Therapies Patent Analysis: Top CPC Sections
Table 19.2 CAR-T Therapies Patent Analysis: Top CPC Symbols
Table 19.3 CAR-T Therapies Patent Analysis: Top CPC Codes
Table 19.4 CAR-T Therapies Patent Analysis: Summary of Benchmarking Analysis
Table 19.5 CAR-T Therapies Patent Analysis: Categorization based on Weighted Valuation Scores
Table 19.6 CAR-T Therapies Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 19.7 CAR-T Therapies Patent Portfolio: List of Leading Patents (By Number of Citations)
Table 19.8 TCR-based Therapies Patent Analysis: Prominent CPC Symbols
Table 19.9 TCR-based Therapies Patent Analysis: Most Popular CPC Symbols
Table 19.10 TCR-based Therapies Patent Analysis: List of Top CPC Symbols
Table 19.11 TCR-based Therapies Patent Analysis: Summary of Benchmarking Analysis
Table 19.12 TCR-based Therapies Patent Analysis: Categorization based on Weighted Valuation Scores
Table 19.13 TIL-based Therapies Patent Analysis: Prominent CPC Symbols
Table 19.14 TIL-based Therapies Patent Analysis: Most Popular CPC Symbols
Table 19.15 TIL-based Therapies Patent Analysis: List of Top CPC Symbols
Table 19.16 TIL-based Therapies Patent Analysis: Summary of Benchmarking Analysis
Table 19.17 TIL-based Therapies Patent Analysis: Categorization based on Weighted Valuation Scores
Table 20.1 Characteristic Properties of Treg Cells
Table 20.2 Other T-Cell Immunotherapies: Therapy Candidate Pipeline
Table 21.1 Assessment Strategies for Different Manufacturing Processes
Table 21.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 21.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers
Table 22.1 Price of Marketed Gene / Cell Therapies
Table 22.2 Price of Marketed Targeted Drugs
Table 22.3 T-Cell Immunotherapies: Expert Opinions on Pricing
Table 22.4 CAR-T Therapies: Reimbursement Landscape
Table 23.1 T-Cell Therapies Market: List of Forecasted Therapies
Table 31.1 Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Table 31.2 Kymriah®: Drug Overview
Table 31.3 Yescarta®: Drug Overview
Table 31.4 Tecartus™: Drug Overview
Table 31.5 Breyanzi®: Drug Overview
Table 31.6 Abecma: Drug Overview
Table 31.7 Carvykti: Drug Overview
Table 31.8 Kimmtrak: Drug Overview
Table 32.1 Global T-cell (CAR-T, TCR and TIL) Therapies Market: List of Developers Profiled
Table 32.2 Adaptimmune Therapeutics: Company Profile
Table 32.3 AbelZeta: Company Profile
Table 32.4 Alaunos Therapeutics: Company Profile
Table 32.5 Autolus Therapeutics: Company Profile
Table 32.6 bluebird bio: Company Profile
Table 32.7 Bristol Myers Squibb: Company Profile
Table 32.8 CARsgen Therapeutics: Company Profile
Table 32.9 Cellectis: Company Profile
Table 32.10 Gilead Sciences: Company Profile
Table 32.11 Immatics: Company Profile
Table 32.12 Immunocore: Company Profile
Table 32.13 Innovative Cellular Therapeutics: Company Profile
Table 32.14 Iovance Biotherapeutics: Company Profile
Table 32.15 Kuur Therapeutics: Company Profile
Table 32.16 Lion TCR: Company Profile
Table 32.17 Noile-Immune Biotech: Company Profile
Table 32.18 Novartis: Company Profile
Table 32.19 Takara Bio: Company Profile
Table 32.20 Wellington Zhaotai Therapies: Company Profile
Table 32.21 Zelluna Immunotherapy: Company Profile
Table 35.1 CAR-T Therapies: Distribution by Stage of Development
Table 35.2 CAR-T Therapies: Distribution by Type of Therapy
Table 35.3 CAR-T Therapies: Distribution by Target Antigen
Table 35.4 CAR-T Therapies: Distribution by Target Indication
Table 35.5 CAR-T Therapies: Distribution by Therapeutic Area
Table 35.6 CAR-T Therapies: Distribution by Stage of Development and Therapeutic Area
Table 35.7 CAR-T Therapies: Distribution by Source of T-cells
Table 35.8 CAR-T Therapies: Distribution by Stage of Development and Source of T-cells
Table 35.9 CAR-T Therapies: Distribution by Route of Administration
Table 35.10 CAR-T Therapies: Distribution by Dosing Frequency
Table 35.11 CAR-T Therapies: Distribution by Target Patient Segment
Table 35.12 Most Active Industry Players: Distribution by Number of CAR-T Therapies Developed
Table 35.13 Most Active Non-Industry Players: Distribution by Number of CAR-T Therapies Developed
Table 35.14 CAR-T Therapy Developers: Distribution by Year of Establishment
Table 35.15 CAR-T Therapy Developers: Distribution by Company Size
Table 35.16 CAR-T Therapy Developers: Distribution by Location of Headquarters (Region)
Table 35.17 CAR-T Therapy Developers: Distribution by Location of Headquarters (Country)
Table 35.18 TCR-based Therapies: Distribution by Stage of Development
Table 35.19 TCR-based Therapies: Distribution by Therapeutic Area
Table 35.20 TCR-based Therapies: Distribution by Stage of Development and Therapeutic Area
Table 35.21 TCR-based Therapies: Distribution by Target Indication
Table 35.22 TCR-based Therapies: Distribution by Target Antigen
Table 35.23 TCR-based Therapies: Distribution by Source of T-Cells
Table 35.24 TCR-based Therapies: Distribution by Route of Administration
Table 35.25 TCR-based Therapies: Distribution by Dosing Frequency
Table 35.26 TCR-based Therapies: Distribution by Target Patient Segment
Table 35.27 TCR-based Therapies: Distribution by Type of Therapy
Table 35.28 TCR-based Therapies: Distribution by Stage of Development and Type of Therapy
Table 35.29 Most Active Industry Players: Distribution by Number of TCR-based Therapies Developed
Table 35.30 Most Active Non-Industry Players: Distribution by Number of TCR-based Therapies Developed
Table 35.31 TCR-based Therapy Developers: Distribution by Year of Establishment
Table 35.32 TCR-based Therapy Developers: Distribution by Company Size
Table 35.33 TCR-based Therapy Developers: Distribution by Location of Headquarters
Table 35.34 TIL-based Therapies: Distribution by Type of Developer
Table 35.35 TIL-based Therapies: Distribution by Stage of Development
Table 35.36 TIL-based Therapies: Distribution by Route of Administration
Table 35.37 TIL-based Therapies: Distribution by Dosing Frequency
Table 35.38 TIL-based Therapies: Distribution by Target Patient Segment
Table 35.39 TIL-based Therapies: Distribution by Type of Therapy
Table 35.40 TIL-based Therapies: Distribution by Target Indication
Table 35.41 Most Active Industry Players: Distribution by Number of TIL-based Therapies Developed
Table 35.42 Most Active Non-Industry Players: Distribution by Number of TIL-based Therapies Developed
Table 35.43 TIL-based Therapy Developers: Distribution by Year of Establishment
Table 35.44 TIL-based Therapy Developers: Distribution by Company Size
Table 35.45 TIL-based Therapy Developers: Distribution by Location of Headquarters
Table 35.46 CAR-Construction: Distribution by Generation of CAR
Table 35.47 CAR-Construction: Distribution by Type of scFv Antibody Used
Table 35.48 CAR-Construction: Distribution by Type of Virus Used
Table 35.49 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Table 35.50 CAR-Construction: Distribution by Type of Co-Stimulatory Domain
Table 35.51 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2017
Table 35.52 Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year, Since 2017
Table 35.53 Clinical Trial Analysis: Distribution by Trial Phase
Table 35.54 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Phase
Table 35.55 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Since 2017
Table 35.56 Clinical Trial Analysis: Distribution by Trial Status
Table 35.57 Clinical Trial Analysis: Distribution by Patient Gender
Table 35.58 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 35.59 Clinical Trial Analysis: Distribution by Type of Trial Masking
Table 35.60 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 35.61 Clinical Trial Analysis: Distribution by Trial Purpose
Table 35.62 Clinical Trial Analysis: Distribution by Design Allocation
Table 35.63 Leading Industry Players: Distribution by Number of Registered Trials
Table 35.64 Leading Non-Industry Players: Distribution by Number of Registered Trials
Table 35.65 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Table 35.66 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Table 35.67 TCR-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since 2017
Table 35.68 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Patient Enrolled, Since 2017
Table 35.69 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Table 35.70 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Since 2017
Table 35.71 TCR-based Therapies Clinical Trial Analysis: Distribution of Number of Trials by Trial Phase
Table 35.72 TCR-based Therapies Clinical Trial Analysis: Distribution of Patient Enrolled by Trial Phase
Table 35.73 TCR-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Table 35.74 TCR-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 35.75 TCR-based Therapies Clinical Trial Analysis: Distribution by Study Design
Table 35.76 Most Active Industry Players: Distribution by Number of Registered Trials
Table 35.77 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 35.78 TCR-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 35.79 TCR-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 35.80 TCR-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 35.81 TCR-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 35.82 TIL-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since 2017
Table 35.83 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Patient Enrolled, Since 2017
Table 35.84 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Table 35.85 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Since 2017
Table 35.86 TIL-based Therapies Clinical Trial Analysis: Distribution of Number of Trials by Trial Phase
Table 35.87 TIL-based Therapies Clinical Trial Analysis: Distribution of Patient Enrolled by Trial Phase
Table 35.88 TIL-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Table 35.89 TIL-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 35.90 TIL-based Therapies Clinical Trial Analysis: Distribution by Study Design
Table 35.91 Most Active Players: Distribution by Number of Registered Trials
Table 35.92 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 35.93 TIL-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 35.94 TIL-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 35.95 TIL-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 35.96 TIL-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 35.97 CAR-T Therapies KOL Analysis: Distribution by Type of Organization
Table 35.98 CAR-T Therapies KOL Analysis: Distribution by Affiliated Organization
Table 35.99 CAR-T Therapies KOL Analysis: Distribution by Qualification
Table 35.100 CAR-T Therapies KOL Analysis: Distribution by Geography
Table 35.101 CAR-T Therapies Most Prominent KOLs: Distribution by RA Score
Table 35.102 CAR-T Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 35.103 TCR-based Therapies KOL Analysis: Distribution by Type of Organization
Table 35.104 TCR-based Therapies KOL Analysis: Distribution by Affiliated Organization
Table 35.105 TCR-based Therapies KOL Analysis: Distribution by Qualification
Table 35.106 TCR-based Therapies KOL Analysis: Distribution by Geography
Table 35.107 TCR-based Therapies Most Prominent KOLs: Distribution by RA Score
Table 35.108 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 35.109 TIL-based Therapies KOL Analysis: Distribution by Type of Organization
Table 35.110 TIL-based Therapies KOL Analysis: Distribution by Affiliated Organization
Table 35.111 TIL-based Therapies KOL Analysis: Distribution by Qualification
Table 35.112 TIL-based Therapies KOL Analysis: Distribution by Geography
Table 35.113 TIL-based Therapies Most Prominent KOLs: Distribution by RA Score
Table 35.114 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 35.115 Kymriah®: Estimated Sales Revenues
Table 35.116 Yescarta®: Estimated Sales Revenues
Table 35.117 Tecartus™: Estimated Sales Revenues
Table 35.118 Breyanzi®: Estimated Sales Revenues
Table 35.119 Abecma®: Estimated Sales Revenues
Table 35.120 Carvykti®: Estimated Sales Revenues
Table 35.121 Carteyva®: Estimated Sales Revenues
Table 35.122 AUTO1: Estimated Sales Revenues
Table 35.123 AUTO3: Estimated Sales Revenues
Table 35.124 Kimmtrak®: Estimated Sales Revenues
Table 35.125 GSK3377794: Estimated Sales Revenues
Table 35.126 ADP-A2M4: Estimated Sales Revenues
Table 35.127 TBI-1301: Estimated Sales Revenues
Table 35.128 LN-144: Estimated Sales Revenues
Table 35.129 LN-145: Estimated Sales Revenues
Table 35.130 ITIL-168: Estimated Sales Revenues
Table 35.131 LTX-315: Estimated Sales Revenues
Table 35.132 Partnerships and Collaborations: Cumulative Year-Wise Trend, Since 2015
Table 35.133 Partnerships and Collaborations: Distribution by Type of Partnership
Table 35.134 Partnerships and Collaborations: Distribution by Type of Partnership, Since 2015
Table 35.135 Partnerships and Collaborations: Distribution by Type of Product
Table 35.136 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
Table 35.137 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 35.138 Partnerships and Collaborations: Distribution by Type of Partner
Table 35.139 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner
Table 35.140 Partnerships and Collaborations: Distribution by Type of Product and Type of Partner
Table 35.141 Most Popular Products: Distribution by Number of Partnerships
Table 35.142 Most Active Industry Players: Distribution by Number of Partnerships
Table 35.143 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 35.144 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Table 35.145 Partnerships and Collaborations: Distribution of International and Local Agreements
Table 35.146 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Since 2018
Table 35.147 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Since 2018 (USD Million)
Table 35.148 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 35.149 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 35.150 Funding and Investments: Distribution of Amount Invested by Type of Therapy, Since 2018 (USD Million)
Table 35.151 Funding and Investments: Distribution by Type of Investors
Table 35.152 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Table 35.153 Most Active Players: Distribution by Number of Instances
Table 35.154 Most Active Players: Distribution by Amount Invested (USD Million)
Table 35.155 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Table 35.156 Most Active Investors: Distribution by Number of Funding Instances
Table 35.157 Patent Analysis: Distribution by Type of Patent
Table 35.158 CAR-T Therapies Patent Analysis: Distribution by Patent Publication Year, Since 2017
Table 35.159 CAR-T Therapies Patent Analysis: Distribution by Patent Application Year, Since 2017
Table 35.160 CAR-T Therapies Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, Since 2017
Table 35.161 CAR-T Therapies Patent Analysis: Distribution by Patent Jurisdiction
Table 35.162 CAR-T Therapies Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 35.163 Leading Industry Players: Distribution by Number of Patents
Table 35.164 Leading Non-Industry Players: Distribution by Number of Patents
Table 35.165 Leading Individual Assignees: Distribution by Number of Patents
Table 35.166 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Table 35.167 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Table 35.168 CAR-T Therapies Patent Analysis: Distribution by Patent Age
Table 35.169 CAR-T Therapy: Patent Valuation
Table 35.170 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 35.171 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Table 35.172 TCR-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 35.173 TCR-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 35.174 TCR-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted Patents
Table 35.175 TCR-based Therapies Patent Analysis: Distribution by Geography
Table 35.176 TCR-based Therapies Patent Analysis: Distribution by Type of Player
Table 35.177 TCR-based Therapies Patent Analysis: Distribution by CPC Symbols
Table 35.178 Leading Industry Players: Distribution by Number of Patents
Table 35.179 Leading Non-Industry Players: Distribution by Number of Patents
Table 35.180 Leading Patent Assignees: Distribution by Number of Patents
Table 35.181 Patent Analysis: Distribution by Patent Age
Table 35.182 TCR-based Therapies: Patent Valuation Analysis
Table 35.183 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 35.184 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Table 35.185 TIL-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 35.186 TIL-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 35.187 TIL-based Therapies Patent Analysis: Distribution by Year-wise filed Patent Applications and Granted patents
Table 35.188 TIL-based Therapies Patent Analysis: Distribution by Geography
Table 35.189 TIL-based Therapies Patent Analysis: Distribution by Type of Player
Table 35.190 TIL-based Therapies Patent Analysis: Distribution by CPC Symbols
Table 35.191 Leading Industry Players: Distribution by Number of Patents
Table 35.192 Leading Non-Industry Players: Distribution by Number of Patents
Table 35.193 Leading Patent Assignees: Distribution by Number of Patents
Table 35.194 Patent Analysis: Distribution by Patent Age
Table 35.195 Other T-Cell Immunotherapies: Analysis by Type of T-Cell
Table 35.196 Other T-Cell Immunotherapies: Analysis by Source of T-Cells
Table 35.197 Other T-Cell Immunotherapies: Distribution by Stage of Development
Table 35.198 Other T-Cell Immunotherapies: Distribution by Therapeutic Area
Table 35.199 Global T-Cell Therapies Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 35.200 Global T-Cell Therapies Market, (till 2035): Conservative Scenario (USD Billion)
Table 35.201 Global T-Cell Therapies Market, (till 2035): Optimistic Scenario (USD Billion)
Table 35.202 T-Cell Therapies Market for CAR-T: Historical Trends (since 2018) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.203 T-Cell Therapies Market for TCR: Historical Trends (since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.204 T-Cell Therapies Market for TIL: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 35.205 CAR-T Therapies Market for Multiple Myeloma: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.206 CAR-T Therapies Market for Large B-cell Lymphoma: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.207 CAR-T Therapies Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.208 CAR-T Therapies Market for Diffuse Large B-cell Lymphoma: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.209 CAR-T Therapies Market for Diffuse Large B-cell Lymphoma, Large B-cell Lymphoma: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.210 CAR-T Therapies Market for Acute Lymphoblastic Leukemia/ B-cell Non-Hodgkin Lymphoma: Forecasted Estimates (2029-2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.211 CAR-T Therapies Market for Non-Hodgkin Lymphoma: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.212 CAR-T Therapies Market for Mantle Cell Lymphoma: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.213 CAR-T Therapies Market for Acute Myeloid Leukemia: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.214 CAR-T Therapies Market for Generalized Myasthenia Gravis: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.215 CAR-T Therapies Market for Renal transplantation: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.216 CAR-T Therapies Market for Gastric Adenocarcinoma: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.217 CAR-T Therapies Market for Ovarian and endometrial cancer: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.218 CAR-T Therapies Market for Chronic Lymphocytic Leukemia: Forecasted Estimates (2027-2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.219 CAR-T Therapies Market for Follicular Lymphoma: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.220 CAR-T Therapies Market for Renal Cell Carcinoma: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.221 TCR Therapies Market for Melanoma: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.222 TCR Therapies Market for Sarcoma: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.223 TCR Therapies Market for Head and Neck Cancer: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.224 TCR Therapies Market for Hepatocellular Carcinoma: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.225 TCR Therapies Market for Nasopharyngeal Carcinoma: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.226 TCR Therapies Market for Ovarian Cancer: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.227 TCR Therapies Market for Acute Myeloid Leukemia: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.228 TIL Therapies Market for Melanoma: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.229 TIL Ther Therapies apy Market for Basal Cell Carcinoma: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.230 TIL Therapies Market for Lung Cancer: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.231 TIL Therapies Market for Sarcoma: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.232 TIL Therapies Market for Head and Neck Cancer: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.233 TIL Therapies Market for Cervical Cancer: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.234 TIL Therapies Market for Neuro Gastro-Intestinal (GI) Cancer: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.235 TIL Therapies Market for Breast Cancer: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.236 CAR-T Therapies Market for BCMA: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.237 CAR-T Therapies Market for CD19: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.238 CAR-T Therapies Market for CD20: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.239 CAR-T Therapies Market for CD19 / CD22: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.240 CAR-T Therapies Market for Other Antigens: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.241 TCR Therapies Market for HLA: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.242 TCR Therapies Market for MAGE: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.243 TCR Therapies Market for PRAME: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.244 TCR Therapies Market for NY-ESO-1 and LAGE: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.245 TCR Therapies Market for EBV: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.246 TCR Therapies Market for HBV: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.247 TCR Therapies Market for Mid-Sized Companies: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.248 TCR Therapies Market for Large Companies: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.249 TIL Therapies Market for Small Companies: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.250 TIL Therapies Market for Large Companies: Forecasted Estimates (till 2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.251 CAR-T Therapies Market in North America: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.252 CAR-T Therapies Market in Europe: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.253 CAR-T Therapies Market in Asia Pacific: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.254 CAR-T Therapies Market in Latin America: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.255 CAR-T Therapies Market in Middle East and North Africa: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.256 CAR-T Therapies Market in Rest of the World: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.257 TCR Therapies Market in North America: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.258 TCR Therapies Market in Europe: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.259 TCR Therapies Market in Asia-Pacific: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.260 TCR Therapies Market in Rest of the World: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.261 TIL Therapies Market in North America: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.262 TIL Therapies Market in Europe: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.263 TIL Therapies Market in Rest of the World: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.264 CAR-T Therapies Market: Gilead Sciences Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.265 CAR-T Therapies Market: Bristol Myers Squibb Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.266 CAR-T Therapies Market: Novartis Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.267 CAR-T Therapies Market: Janssen Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.268 CAR-T Therapies Market: JW Therapeutics Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.269 TCR Therapies Market: Immunocore Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.270 TCR Therapies Market: Adaptimmune Therapeutics Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.271 TCR Therapies Market: TCRCure Biopharma Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.272 TCR Therapies Market: Lion TCR Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.273 TCR Therapies Market: Miltenyi Biomedicine Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.274 TIL Therapies Market: Iovance Biotherapeutics Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.275 TIL Therapies Market: Lytix Biopharma Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.276 TIL Therapies Market: Bristol-Myers Squibb Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.277 TIL Therapies Market: Intima Bioscience Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.278 CAR-T Therapies Market: Kymriah (Tisagenlecleucel-T) Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.279 CAR-T Therapies Market: Yescarta (axicabtagene ciloleucel) Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.280 CAR-T Therapies Market: Tecartus (Brexucabtagene Autoleucel) Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.281 CAR-T Therapies Market: Abecma (Idecabtagene Vicleucel / bb2121) Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.282 CAR-T Therapies Market: CARVYKTI (LCAR-B38M CAR-T / JNJ-68284528 / Ciltacabtagene Autoleucel) Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.283 CAR-T Therapies Market: BREYANZI (Lisocabtagene maraleucel, JCAR017) Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.284 CAR-T Therapies Market: Carteyva (Relmacabtagene autoleucel / JWCAR029) Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.285 CAR-T Therapies Market: NexCART Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.286 CAR-T Therapies Market: Fucaso (Equecabtagene Autoleucel) Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.287 CAR-T Therapies Market: Inaticabtagene Autoleucel CNCT19 / HY001 Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.288 CAR-T Therapies Market: Zevorcabtagene autoleucel (CT053) Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.289 CAR-T Therapies Market: CAR-BCMA T cells Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.290 CAR-T Therapies Market: CAR-T-CD19 Cells Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.291 CAR-T Therapies Market: Descartes-08 Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.292 CAR-T Therapies Market: Zamtocabtagene Autoleucel (MB-CART2019.1) Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.293 CAR-T Therapies Market: CAR-T ddBCMA Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.294 CAR-T Therapies Market: CRG-022 cells Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.295 CAR-T Therapies Market: CT041 Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.296 CAR-T Therapies Market: ALLO-501A / ALLO-501 Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.297 CAR-T Therapies Market: ALLO-605 Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.298 CAR-T Therapies Market: Descartes-25 Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.299 CAR-T Therapies Market: AUTO1 Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.300 CAR-T Therapies Market: AUTO3 (CD19/22 CAR-T) Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.301 CAR-T Therapies Market: AUTO4 (CD19/22 CAR-T) Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.302 CAR-T Therapies Market: CD19-CAR-T Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.303 CAR-T Therapies Market: Humanized CD19-CAR-T Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.304 CAR-T Therapies Market: IM19 CAR-T Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.305 CAR-T Therapies Market: CCT301 CAR-T Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.306 CAR-T Therapies Market: CARCIK-CD19 Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.307 CAR-T Therapies Market: CD123 CAR-Ts Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.308 CAR-T Therapies Market: BCMA CAR-T Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.309 CAR-T Therapies Market: CD19/CD22-CAR-T Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.310 CAR-T Therapies Market: GC012F (Dual CAR-BCMA-19) Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.311 TCR Therapies Market: Kimmtrak (IMCgp100 / Tebentafusp) Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.312 TCR Therapies Market: TECELRA® (Afamitresgene Autoleucel) Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.313 TCR Therapies Market: Brenetafusp (IMC-F106C) Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.314 TCR Therapies Market: lete-cel Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.315 TCR Therapies Market: ADP-A2M4CD8 Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.316 TCR Therapies Market: EBV-specific TCR-T cell with anti-PD1 auto-secreted element Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.317 TCR Therapies Market: Unnamed TCR Therapy Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.318 TCR Therapies Market: MB-dNPM1 Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.319 TIL Therapies Market: AMTAGVI Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.320 TIL Therapies Market: LN-145 Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.321 TIL Therapies Market: IOV-4001 Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.322 TIL Therapies Market: LTX-315 and TILs Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.223 TIL Therapies Market: TILs Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 35.324 TIL Therapies Market: TIL (Cyclophosphamide) Sales Forecast (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Adaptimmune Therapeutics
AbelZeta
Alaunos Therapeutics
Autolus Therapeutics
bluebird bio
Bristol Myers Squibb
CARsgen Therapeutics
Cellectis
Gilead Sciences
Immatics
Immunocore
Innovative Cellular Therapeutics
Iovance Biotherapeutics
Kuur Therapeutics
Lion TCR
Noile-Immune Biotech
Novartis
Takara Bio
Wellington Zhaotai Therapies
Zelluna immunotherapy

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€4562EUR$4,799USD£3,833GBP
SITE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6654EUR$6,999USD£5,590GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€17111EUR$17,999USD£14,375GBP